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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
percutaneous Coronary Interventions
Percutaneous coronary angioplasty was first introduced by Andreas Gruentzig in 1977 as a 
non surgical method for coronary artery revascularization. Although initially restricted to stable 
patients with single, discrete, concentric, noncalcified stenoses, percutaneous revascularization 
is now routinely applied to patients with multivessel disease, multiple lesions, complex lesions, 
acute coronary syndromes, and left ventricular dysfunction. Refinement of the equipment used 
to perform angioplasty and utilization of adjunctive periprocedural medications, together with 
time and growing experience played a major role in the explosive growth and popularity of 
percutaneous coronary interventions (PCI). The most important advancement in the field of 
percutaneous coronary interventions was the introduction of coronary stents, which reduce both 
the acute risk of major complications and the incidence of restenosis.1,2 With modern techniques, 
procedural success > 90% is readily achieved, and the risk of sudden arterial occlusion and 
subsequent myocardial infarction is very low.3 Long-term survival has been shown to be not 
different from that achieved with bypass surgery, therefore in many countries percutaneous 
coronary interventions have become the preferred strategy for coronary revascularization.
Restenosis
Restenosis, defined as the vessel lumen renarrowing following a successful percutaneous 
coronary intervention, represents the principal limitation to the long-term outcome of coronary 
angioplasty. Restenosis is a pathobiological process caused by the arterial healing response 
after vessel injury, and is due to varying degrees of elastic recoil,4 vascular remodeling,5 
and neointimal hyperplasia.6 The only widely accepted means of reducing restenosis is the 
coronary stent, which virtually eliminates vessel elastic recoil and negative remodeling following 
balloon dilatation.6 However, the efficacy of this purely “mechanical” approach to the prevention 
of restenosis has been hampered by the development of a new iatrogenic disease: in-stent 
restenosis, which is predominantly due to neointima formation. In-stent restenosis has been 
reported to occur in 10 to 50% of the patients in several series, 7 depending upon a number 
of clinical, angiographic, and procedural variables. Furthermore, treatment of ISR is frequently 
a challenging clinical problem, with recurrent restenosis being reported in up to 80% of the 
patients in the most complex cases. 8
The development of neointimal tissue is thought to relate to a combination of coagulation 
cascade activation, platelet deposition, organization of thrombus, growth factor stimulation, and 
is due mainly to smooth muscle cell proliferation and migration, and excessive extracellular 
matrix production. 9 Smooth muscle cell proliferation has therefore become the main target in 
the effort to prevent or reduce in-stent restenosis.
DRUG-ELUTING STENTS
Stent-based local drug delivery (drug-eluting stents) is a percutaneous technique that has been 
developed to prevent neointimal proliferation. 10 Stents represent an ideal platform for local drug 
delivery because of their permanent scaffolding properties. In addition, they may represent drug 
reservoirs as medications are released to the vessel wall from various coatings at different time 
intervals. The drugs which have been tested can be classified according to the mechanism of 
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action as immunosuppressive, antiproliferative, antiinflammatory, antithrombotic. Some agents, 
such as sirolimus, may affect multiple targets. 11 Recently, sirolimus- and paclitaxel-eluting stent 
implantation has been proven to markedly reduce the incidence of angiographic restenosis and 
repeat revascularization when compared to bare metal stents in selected patients, 12-15 raising 
considerable enthusiasm in the scientific community.
Immediately after market approval in Europe and FDA approval in the USA, drug-eluting 
stents have triggered a major debate regarding their correct utilization. Evidence-based 
medicine, cost-effectiveness ratio, and necessity to complete scientific evaluation in every 
subset of patients and lesions, have resulted in different strategies between different countries 
and different hospitals.16-18
The present doctoral research project started after sirolimus-eluting stents (CypherTM, 
Cordis Europe, Johnson and Johnson, Roden, NL) were commercialised in Europe. The 
Thoraxcenter, Erasmus University of Rotterdam, had played a pivotal role in the First in Men 
(FIM) 19,20 and in the RAndomized study with the sirolimus-eluting Bx VElocity balloon-expandable 
stent in the treatment of patients with de novo native coronary artery Lesions (RAVEL)12 trials, 
being among the pioneers of drug-eluting stents development. The dilemma about drug-eluting 
stent utilization was subsequently turned into a scientific research program aimed to evaluate 
the impact in clinical practice of routine drug-eluting stent implantation, without any clinical 
and anatomical restriction, the Rapamycin Eluting Stents Evaluated At Rotterdam Cardiology 
Hospital (RESEARCH) registry. 18 Most of the studies which compose this thesis were performed 
in this setting.
In-Stent Restenosis and Acute Myocardial Infarction: the past and the Future
In-stent restenosis (ISR) and acute myocardial infarction (AMI) could be seen as two “boundaries” 
of drug-eluting stents utilization because of many different reasons.
From a clinical point of view, ISR more often lead to chronic ischemic coronary disease/
stable angina, whilst AMI is the most dramatic of the acute coronary syndromes.
Pathophysiology of these two conditions is also extremely different: exaggerated neointimal 
hyperplasia following stent implantation is responsible of ISR, whilst atherosclerotic plaque 
rupture/erosion with superimposition of a flow-limiting thrombus is the predominant cause of 
AMI.21 The biological substrate and target of the intervention is therefore clearly different.
In-stent restenosis and acute myocardial infarction are boundaries for drug-eluting stent 
utilization also from a “strategic” point of view. In fact, many institutions are carefully selecting 
patients to be treated with drug-eluting stents, limiting DES implantation to a few specific 
indication, and treatment of ISR on a bare stent was one of the first indications proposed. At 
the other extreme of the spectrum of possible treatment strategies, there are institutions with a 
broad and liberal utilization of DES, including patients with AMI.
Furthermore, percutaneous treatment of ISR and AMI might delineate a peculiar temporal, 
historical perspective. In-stent restenosis is presently considered the Achille’s heel of 
interventional cardiology.22 If the results of DES utilization in selected populations were confirmed 
in the daily practice, in-stent restenosis rate could be reduced to a single digit number and even 
more reduced should be the necessity of repeat revascularization. Since restenosis following 
DES implantation seems to be predominantly focal, ISR as a major limitation of PCI might 
become just history of the past. 23,24 On the other hand, percutaneous angioplasty has been 
recently indicated as the preferred therapeutic option to obtain culprit vessel recanalization 
during acute myocardial infarction, at least when it can be performed within 90 min after the first 
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medical contact. In the last few years, a tremendous interest has been focused on catheter-
based reperfusion therapy for myocardial infarction, involving health system organization, 
financial resorts, and research for new devices and peri-procedural medications. 25 Thus, giving 
a glance into the future of catheterization laboratories, we could hypothesize that treatment of 
acute myocardial infarction will become more and more relevant.
Drug-Eluting Stents to Treat In-stent Restenosis
Prevention of in-stent restenosis is undoubtedly the major frontier of interventional cardiology, 
and drug-eluting stent implantation represents the most promising strategy. However, the 
implementation of drug-eluting stents in clinical practice has been limited manly by cost issues 
and, to a lesser extent, by the reluctance in transferring the positive results of RCTs to the real-
world. Moreover, to date limited data are available for DES utilization in some high-risk patients 
and lesions. Bare metal stents are still the most used devices in the catheterization laboratory, 
and development of in-stent restenosis is still a major problem. Vascular brachytherapy is the 
only percutaneous treatment proven to be effective to treat in-stent restenosis in randomized 
trials. 26-30 However, its utilization is limited by complex logistic requirements and the necessity of 
highly trained operators. Drug-eluting stents have been proposed as an alternative to vascular 
brachytherapy, because of the potent inibitory effect on developement of neointimal hyperplasia. 
31-33 In the first part of this thesis, we analysed the preliminary results of this new strategy.
Unrestricted Utilization Of Drug-Eluting Stents
The second part of this doctoral research is focused on the evaluation of unrestricted utilization of 
drug-eluting stents to prevent in-stent restenosis. Specifically, we analyzed safety, effectiveness 
and caveats of sirolimus-eluting stent implantation as the default strategy to accomplish 
percutaneous coronary interventions at our catheterization laboratory, without any clinical or 
anatomical restriction.
Drug-Eluting Stents For ST-Elevation Acute Myocardial Infarction
Patients presenting with acute myocardial infarction form a peculiar cohort of patients undergoing 
percutaneous coronary interventions, because of the high-risk of periprocedural and mid-term 
complications.
We investigated the clinical and angiographic results of sirolimus-eluting stent implantation 
in patients with ST-elevation acute myocardial infarction. The results of our researches are 
described in Part 3 of this thesis.
14
Chapter 1
REFERENCES
1.  Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, 
Marco J, Legrand V, Materne P, et al. A comparison of balloon-expandable-stent implantation 
with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N 
Engl J Med 1994;331:489-95.
2.  Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci 
D, Nobuyoshi M, et al. A randomized comparison of coronary-stent placement and balloon 
angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. 
N Engl J Med 1994;331:496-501.
3.  Smith SC, Jr., Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, Kuntz RE, Popma 
JJ, Schaff HV, Williams DO, Gibbons RJ, Alpert JP, Eagle KA, Faxon DP, Fuster V, Gardner 
TJ, Gregoratos G, Russell RO. ACC/AHA guidelines of percutaneous coronary interventions 
(revision of the 1993 PTCA guidelines)--executive summary. A report of the American College 
of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to 
revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll 
Cardiol 2001;37:2215-39.
4.  Rensing BJ, Hermans WR, Beatt KJ, Laarman GJ, Suryapranata H, van den Brand M, 
de Feyter PJ, Serruys PW. Quantitative angiographic assessment of elastic recoil after 
percutaneous transluminal coronary angioplasty. Am J Cardiol 1990;66:1039-44.
5.  Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, Hong MK, Kovach JA, Leon 
MB. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. 
Circulation 1996;94:35-43.
6.  Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, 
Leon MB. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound 
study. Circulation 1996;94:1247-54.
7. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and 
future strategies. J Am Coll Cardiol 2002;39:183-93.
8. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone 
GW, Leon MB. Angiographic patterns of in-stent restenosis: classification and implications for 
long-term outcome. Circulation 1999;100:1872-8.
9.  Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A, Kolodgie FD, Colombo 
A. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting 
polymer stent system in humans. Circulation 2002;106:2649-51.
10.  Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. 
Circulation 2003;107:2274-9.
11.  Serruys PW, Regar E, Carter AJ. Rapamycin eluting stent: the onset of a new era in 
interventional cardiology. Heart 2002;87:305-7.
12.  Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, 
Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a 
sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 
2002;346:1773-80.
13.  Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo 
RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents 
versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 
2003;349:1315-23.
14.  Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G. Sirolimus-
eluting stents for treatment of patients with long atherosclerotic lesions in small coronary 
arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
15.  Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, 
Schiele F, Zmudka K, Guagliumi G, Russell ME. Randomized study to assess the effectiveness 
of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery 
lesions. Circulation 2003;108:788-94.
16.  Lemos PA, Serruys PW, Sousa JE. Drug-eluting stents: cost versus clinical benefit. Circulation 
2003;107:3003-7.
Introduction and Overview of the Thesis 
15
17.  O’Neill WW, Leon MB. Drug-eluting stents: costs versus clinical benefit. Circulation 
2003;107:3008-11.
18.  Lemos PA, Lee C, Degertekin M, Saia F, Tanabe K, Arampatzis CA, Hoye A, van Duuren M, 
Sianos G, Smits PC, de Feyter P, van der Giessen WJ, van Domburg RT, Serruys PW. Early 
outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes. 
Insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital 
(RESEARCH) registry. J Am Coll Cardiol 2003;41:2093-9.
19.  Rensing BJ, Vos J, Smits PC, Foley DP, van den Brand MJ, van der Giessen WJ, de Feijter 
PJ, Serruys PW. Coronary restenosis elimination with a sirolimus eluting stent: first European 
human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur 
Heart J 2001;22:2125-30.
20.  Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos 
LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. Lack of Neointimal Proliferation 
After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries : A Quantitative 
Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study. Circulation 
2001;103:192-195.
21.  Davies MJ, Thomas AC. Plaque fissuring--the cause of acute myocardial infarction, sudden 
ischaemic death, and crescendo angina. Br Heart J 1985;53:363-73.
22.  Beyar R, Roguin A. The sirolimus coated stent: will the Achilles heel of interventional cardiology 
finally be cured? Eur Heart J 2001;22:2054-7.
23.  Colombo A, Orlic D, Stankovic G, Corvaja N, Spanos V, Montorfano M, Liistro F, Carlino M, 
Airoldi F, Chieffo A, Di Mario C. Preliminary observations regarding angiographic pattern of 
restenosis after rapamycin-eluting stent implantation. Circulation 2003;107:2178-80.
24.  Lemos PA, Saia F, Ligthart JM, Arampatzis CA, Sianos G, Tanabe K, Hoye A, Degertekin 
M, Daemen J, McFadden E, Hofma S, Smits PC, De Feyter P, Van Der Giessen WJ, Van 
Domburg RT, Serruys PW. Coronary Restenosis After Sirolimus-Eluting Stent Implantation. 
Morphological Description and Mechanistic Analysis From a Consecutive Series of Cases. 
Circulation 2003.
25.  Topol EJ. Current status and future prospects for acute myocardial infarction therapy. 
Circulation 2003;108:III6-13.
26.  Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, Wong SC, Fish D, Ellis 
S, Holmes DR, Kerieakes D, Kuntz RE. Localized intracoronary gamma-radiation therapy to 
inhibit the recurrence of restenosis after stenting. N Engl J Med 2001;344:250-6.
27.  Verin V, Popowski Y, de Bruyne B, Baumgart D, Sauerwein W, Lins M, Kovacs G, Thomas 
M, Calman F, Disco C, Serruys PW, Wijns W. Endoluminal beta-radiation therapy for the 
prevention of coronary restenosis after balloon angioplasty. The Dose-Finding Study Group. 
N Engl J Med 2001;344:243-9.
28.  Waksman R, Bhargava B, White L, Chan RC, Mehran R, Lansky AJ, Mintz GS, Satler LF, 
Pichard AD, Leon MB, Kent KK. Intracoronary beta-radiation therapy inhibits recurrence of 
in-stent restenosis. Circulation 2000;101:1895-8.
29.  Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, Schatz RA, Guarneri EM, 
Steuterman S, Morris NB, Leon MB, Tripuraneni P. Catheter-based radiotherapy to inhibit 
restenosis after coronary stenting. N Engl J Med 1997;336:1697-703.
30.  Waksman R, White RL, Chan RC, Bass BG, Geirlach L, Mintz GS, Satler LF, Mehran R, 
Serruys PW, Lansky AJ, Fitzgerald P, Bhargava B, Kent KM, Pichard AD, Leon MB. 
Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with 
in-stent restenosis. Circulation 2000;101:2165-71.
31.  Sousa JE, Costa MA, Abizaid A, Sousa AG, Feres F, Mattos LA, Centemero M, Maldonado 
G, Abizaid AS, Pinto I, Falotico R, Jaeger J, Popma JJ, Serruys PW. Sirolimus-eluting stent 
for the treatment of in-stent restenosis: a quantitative coronary angiography and three-
dimensional intravascular ultrasound study. Circulation 2003;107:24-7.
32.  Degertekin M, Saia F, Lemos PA, Arampatzis CA, Serruys PW. Sirolimus-eluting stents for the 
treatment of in-stent restenosis. Minerva Cardioangiol 2003;51:475-84.
33.  Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, 
de Feyter P, Muller R, Regar E, Degertekin M, Ligthart JM, Disco C, Backx B, Russell ME. 
TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated 
in a slow-release polymer formulation. Circulation 2003;107:559-64.
16
Chapter 1
Routine Sirolimus-Eluting Stent Implantation for Unselected In-Stent Restenosis
17
DRUG-ELUTING STENTS 
TO TREAT IN-STENT 
RESTENOSIS
CHAPTER 2
Routine Sirolimus-Eluting Stent Implantation 
for Unselected In-Stent Restenosis: 
Insights From the Rapamycin Eluting Stent 
Evaluated at Rotterdam Cardiology Hospital 
(RESEARCH) Registry
Authors: Francesco Saia, Pedro A. Lemos, 
Chourmouzios A. Arampatzis, Angela Hoye, 
Muzaffer Degertekin, Kengo Tanabe, Georgios 
Sianos, Pieter C. Smits, Willem J. van der Giessen, 
Pim J. de Feyter, Ron T. van Domburg, Patrick W. 
Serruys. 
Heart, in press
PART 1
18
Chapter 2
CHAPTER 2
Routine Sirolimus-Eluting Stent Implantation for Unselected In-Stent Restenosis: 
Insights From the Rapamycin Eluting Stent Evaluated at Rotterdam Cardiology Hospital 
(RESEARCH) Registry
 
Francesco Saia, MD, Pedro A. Lemos, MD, Chourmouzios A. Arampatzis, MD, Angela Hoye, 
MB ChB, MRCP, Muzaffer Degertekin, MD, Kengo Tanabe, MD, Georgios Sianos, MD, Pieter 
C. Smits, MD, PhD, Wim J. van der Giessen, MD, PhD, Pim J. de Feyter, MD, PhD, Ron T. van 
Domburg, PhD, Patrick W. Serruys, MD, PhD.
Department of Invasive Cardiology, Thoraxcenter, Erasmus University Medical Center, 
Rotterdam, The Netherlands
Address for correspondence:
Prof. Patrick W. Serruys
Erasmus MC, Thoraxcenter
Kamer Bd 404
Dr. Molewaterplein 40
3015 GD Rotterdam, The Netherlands
Tel: 0031.10.4635260
Fax: 0031.10.4369154
e-mail: p.w.j.c.serruys@erasmusmc.nl
Running head: Sirolimus-eluting stents for ISR
Total word count: 4021
There is no conflict of interest for any of the authors.
Routine Sirolimus-Eluting Stent Implantation for Unselected In-Stent Restenosis
19
ABSTRACT
Objective: To assess the effectiveness of routine sirolimus-eluting stent (SES) implantation for 
unselected patients with in-stent restenosis (ISR), and to provide preliminary information about 
the angiographic outcome for different lesion subgroups and for different ISR patterns.
Design: Prospective, single-center registry.
Setting: Tertiary referral centre.
Patients: We evaluated 44 consecutive patients (53 lesions) without previous brachytherapy 
that were treated with SES for in-stent restenosis at our institution. Routine angiographic 
follow-up was obtained at 6 months and the incidence of major adverse cardiac events was 
evaluated.
Results: At baseline, 42% of the lesions were focal, 21% diffuse, 26% proliferative, and 11% 
total occlusions. Small vessel size (reference diameter <2.5mm) was present in 49%, long 
lesions (>20mm) in 30%, treatment of bypass grafts in 13%, and bifurcation stenting in 18%. At 
follow-up, post-SES restenosis was observed in 14.6%. No restenosis was observed in focal 
lesions. For more complex lesions, restenosis rates ranged 20-25%. At 1-year follow-up, the 
incidence of death was 0%, myocardial infarction 4.7%, and target lesion revascularisation 
16.3%. Target lesion revascularisation due to restenosis was performed in 11.6%.
Conclusions: Routine sirolimus-eluting stent implantation is highly effective for focal in-stent 
restenosis and appears to be a promising strategy for more complex patterns of restenosis.
Keywords: sirolimus, eluting-stent, in-stent restenosis
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INTRODUCTION
Despite major advances in the field of percutaneous coronary interventions (PCI), long-term 
outcome is still limited by the occurrence of in-stent restenosis (ISR), which has been reported 
to occur in 10 to 50% of the patients in several series.[1] Furthermore, treatment of ISR is 
frequently a challenging clinical problem, with recurrent restenosis being reported in up to 80% 
in the most complex cases.[2] Currently, vascular brachytherapy is the only strategy proven to 
be more effective for the treatment of ISR than other conventional approaches.[3][4][5][6][7] 
However, post-brachytherapy recurrent restenosis has been reported to occur in 17% to 32% 
of patients at 1 year.[3][4][5][6][7] Moreover, despite the relative improvement in outcomes, 
brachytherapy has not been extensively adopted as routine therapy in many centers, mostly 
due to logistic and technical limitations.
Sirolimus-eluting stents (SES) have been shown in randomized trials to virtually abolish in-
stent restenosis in selected patients with de novo lesions.[8][9] Moreover, prolonged (up to 2 
years) inhibition of the proliferative response has been documented in two series of patients 
with non-complex lesions.[10][11] Due to the potent antiproliferative and antimigratory effects 
of the drug on vascular smooth muscle cells and the clinical efficacy demonstrated for de 
novo lesions, SES implantation has been recently tested in two preliminary studies to treat 
in-stent restenosis.[12][13] In one study with 25 relatively non-complex cases, zero recurrent 
binary restenosis was observed after SES.[13] In the other study, among 16 patients with more 
complex lesions, repeat in-stent restenosis was observed in 20% of cases.[12] However, due 
to the limited number of patients in both reports, the outcome in patients with complex lesion 
morphology, a condition commonly seen in daily practice, is currently unclear. 
In the present study, we evaluated the clinical and angiographic outcomes of 44 consecutive 
patients treated with routine SES implantation for in-stent restenosis with a broad range of 
morphological lesion patterns. 
METHODS
patient population
Since the 16th of April 2002, SES implantation has been adopted as the default strategy for 
all patients undergoing PCI at our institution, as part of the RESEARCH (Rapamycin-Eluting 
Stents Evaluated At Rotterdam Cardiology Hospital) Registry.[14] Fourty-four consecutive 
patients without previous brachytherapy were treated for in-stent restenosis during a 6-month 
enrolment period and comprise the present study population. No patient with in-stent restenosis 
was treated in the same period exclusively with other percutaneous devices (e.g. bare metal 
stents, cutting balloon) or with brachytherapy and therefore excluded from this report. The study 
protocol was approved by the hospital ethics committee and is in accordance with the principles 
of Good Clinical Practice for Trials of Medicinal Products in the European Community and the 
Declaration of Helsinki. Written informed consent was given by every patient.
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procedure
The CYPHERTM sirolimus-eluting stent (Cordis Europa NV, Roden, NL) was utilized in all 
patients. The stents were available in lengths of 8, 18 or 33mm and in diameters of 2.25, 2.5, 
2.75 and 3.0mm. All procedures were performed according to standard techniques and the 
final interventional strategy was left to the operator’s discretion. Complete lesion coverage was 
recommended, as well as a small region of overlap of adjacent stents when treating lesions that 
required more than one stent. Periprocedural adjunctive medications were left to the discretion 
of the operator. All patients were pre-treated with aspirin and clopidogrel. Aspirin was maintained 
lifelong and at least 3 months of clopidogrel treatment was recommended thereafter. 
Definitions and Follow-up
Restenotic lesions were angiographically classified by two independent operators according to 
Mehran classification as: 1) focal (<10 mm), 2) diffuse, 3) proliferative, or 4) total occlusion.[2] 
A procedure was considered successful when residual stenosis was < 30% by quantitative 
coronary analysis (QCA) with TIMI flow 3. All patients were requested to undergo an elective 
repeat angiogram after 6 months following a successful procedure. Post-SES binary restenosis 
at follow-up was defined as >50% diameter stenosis occurring in the segment inside the SES 
or within 5-mm segment proximal or distal to the stent. Late luminal loss was calculated as the 
difference between the minimal luminal diameter (MLD) immediately after the procedure and 
the MLD at six months.
Patients were prospectively followed-up to evaluate the incidence of major adverse cardio-
vascular events (MACE), defined as death, myocardial infarction or target lesion revascularisation 
(TLR). Target lesion revascularisation (TLR) was defined as any surgical or percutaneous re-
intervention motivated by a significant luminal narrowing within the stent or in the 5-mm distal 
or proximal peristent segments.
Statistical analysis
Discrete variables are reported as counts and relative percentages and compared with Fisher’s 
exact test. Continuous variables are expressed as mean ± standard deviation and compared 
with the Student T test. A p value < 0.05 was considered to be significant. All tests were two-
tailed. Analyses were performed with SPSS version 8.0 statistical package (SPSS Inc. Chicago, 
IL, USA).
RESULTS
Baseline and procedural data
Baseline clinical characteristics of the 44 patients with ISR are shown in table 1. Diabetes 
was present in 25% of the patients. Clinical presentation was an acute coronary syndrome 
in 27% of cases. A quarter of the patients had previous recurrent episodes of ISR. According 
to the Mehran classification, 42% of the lesions were class I, 21% class II, 26% class III, and 
11% class IV (table 2). Small vessel size (reference diameter < 2.5 mm) was present in 49%, 
long lesions (>20mm) in 30%, treatment of bypass grafts in 13%, and bifurcation stenting in 
18%. The patients received on average 2.0±1.4 stents, with a mean stent length per lesion of 
28±20mm (range 8-84 mm). Direct stenting was performed in 13 lesions (24.5%). Seven lesions 
(13.2%) were pre-dilated with a cutting balloon. Endovascular ultrasound was used in 25% of 
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the procedures for stent sizing or to optimize the result. The procedure was successful in 43 
patients (97.7%). One patient underwent emergency bypass surgery due to intimal dissection 
and acute vessel occlusion during the procedure.
Angiographic results
The pre-procedure, post-procedure and follow-up quantitative angiographic data are shown in 
table 3. Representative sequences of angiograms from two patients are shown in figure 1. Mean 
reference diameter was 2.64±0.56 mm and mean lesion length was 17.5±12.1 mm. Angiographic 
follow-up was obtained in 33 patients (77% of patients with successful index procedure) with 41 
lesions (79%). Late loss was 0.17±0.76 mm. Cumulative distribution curves of angiographic late 
loss (figure 2) show that the vast majority of the lesions (79%) had a late loss between – 0.5 and 
+0.5 mm. Overall, post-SES binary restenosis was observed in 14.6% of the lesions. Table 4 
shows the frequency of post-SES restenosis for some subgroups. No restenosis was observed 
in Mehran class I lesions; class II, III and IV lesions had post-SES restenosis in 22%, 25% and 
20%, respectively (p=NS). In 5 out of 6 cases with post-SES restenosis the restenosis was 
focal or multifocal. For patients with post-SES restenosis, the average lesion length decreased 
from 31.7±15.3mm at baseline to 10.0±4.8mm at follow-up (p=0.01). One patient presented 
post-SES with silent total occlusion. Post-SES restenotic lesions were located within the SES 
in 5 lesions and at the proximal edge in the remaining 1. In two patients, post-SES restenosis 
occurred in an uncovered region injured during the procedure (gap between two SES implanted 
to treat two separate lesions in one patient and stent discontinuity by ultrasound examination 
due to possible stent fracture in another case).[15] Marked SES undersizing (stent diameter 
2.7mm; vessel diameter 5.7mm) was found in another patient with post-SES restenosis.
The patients that developed post-SES restenosis had baseline clinical characteristics similar 
to the others. However, the lesions who developed binary restenosis were considerably longer 
(29.1±15.0 mm vs 16.1±11.0, p=0.01), were treated with more stents (2.2±0.7 vs 1.5±0.7, 
p=0.04), and the stented segment was longer (average stent length per lesion: 49.0±30.0 mm 
vs 25.5±16.3 mm, p<0.01) compared to lesions who presented less than 50% diameter stenosis 
at follow-up.
Clinical Follow-up
Complete clinical follow-up was available for 43 patients (98%). After 1 year, the cumulative 
incidence of MACE was 20.9%. There were no deaths, 2 patients had non-Q-wave myocardial 
infarction (4.7%), of which 1 peri-procedural and 1 after 7 months, and 7 patients (16.3%) 
underwent TLR (including the patient who underwent emergency CABG). Target lesion 
revascularisation due to restenosis was performed in 5 patients (11.6%). One additional target 
lesion revascularisation was performed 5 days after the index procedure in a patient with 
recurrent angina and intravascular ultrasound evidence of incomplete right coronary artery 
ostium coverage. All repeat revascularisations were within 7 months follow-up. There were no 
documented episodes of early or late stent thromboses. It is worth noting that patients who 
refused to undergo angiographic re-evaluation had no adverse events during follow-up.
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DISCUSSION
The major finding of the present study is that routine sirolimus-eluting stent implantation for 
in-stent restenosis is safe and associated with low recurrence rates in a broad range of clinical 
and anatomical settings.
The present series comprises patients and lesions commonly not included in previous 
reports,[12][13] [16] such as very long lesions, chronic total occlusions, small vessels, bypass 
grafts, and bifurcations. In fact, the majority of patients in our consecutive series, representative 
of the everyday practice, presented at least one of the aforementioned characteristics. Despite 
the unselected nature of this population, clinical and angiographic outcomes appear superior to 
previous results for conventional approaches.[2] [18][19][20][21] Indeed, our findings compare 
favorably with those reported for vascular brachytherapy, which has been advocated as the 
treatment of choice for complex in-stent restenosis.[3][4][5][6][7] Moreover, SES implantation 
does not deviate from practice with conventional bare stents, and avoids most of the technical 
and logistical limitations that have hampered a more widespread use of brachytherapy. 
The outcomes of patients with in-stent restenosis after repeat treatment have been reported 
to be closely related to the baseline lesion morphology.[2] A progressive increase in risk profile 
occurs from lesions with a focal pattern to lesions with a more diffuse appearance and total 
occlusions.[2] Accordingly, in our series, SES was associated with a remarkably low incidence 
of recurrent restenosis in focal lesions. Indeed, all cases of repeat restenosis occurred in 
patients with more complex baseline characteristics. However, no clear differences in the rates 
of repeat restenosis were noted among higher risk categories (i.e Mehran classes II, III, and IV), 
in whom the rates of repeat restenosis have been reported to be 35, 50 and 85%, respectively, 
with conventional therapy. Thus, it is possible that SES implantation may reduce the prognostic 
value of the lesion pattern of in-stent restenoses for non-focal ISR, although the limited number 
of our observations does not allow a definitive conclusion. Conversely, our data suggest that 
lesion length may still have an impact on recurrent restenosis. Recently, sirolimus-eluting 
stents have been consistently shown to reduce neointimal proliferation in ISR as effectively 
as in de novo lesions.[21] Instead of reflecting an intrinsic drug resistance, repeat restenosis 
in complex lesions may actually be more closely related to local mechanical conditions that 
impair the therapeutic effect of the device (p.e. incomplete coverage of balloon-injured areas 
of neointimal hyperplasia, under-expanded stents). In fact, a possible technical reason for 
failure was documented in 3 of 6 cases (50%) of recurrent restenosis in our series, although 
the significance of these findings remains elusive. Two recent reports have confirmed these 
observations in a larger number of patients treated with sirolimus-eluting stents. [22][23] 
This study evaluates a relatively limited number of patients and lesions. However, this is the 
largest series of patients described to date (table 5). Moreover, to the best of our knowlegde, 
this is the first study to assess the impact of sirolimus-eluting stent implantation in a broad range 
of different anatomical subsets of in-stent restenosis.
The rate of angiographic follow-up (79% of all lesions), although similar to other studies that 
enrolled patients with recurrent ISR, [3] [6][7] is not very high and could not represent the true 
binary restenosis for the entire cohort. This could be explained by the considerable number of 
recurrent restenosis and previous procedures suffered by some patients, therefore not willing 
to undergo 6-month angiography in the absence of symptoms. This was indirectly confirmed 
by the clinical follow-up of the patients who refused the angiographic control, who were all 
asymptomatic. Patients with failed brachytherapy were not included in the current report. 
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We have recently shown that recurrent in-stent restenosis following vascular brachytherapy 
may exhibit a peculiar and different biological and clinical response to sirolimus-eluting stent 
implantation,[24] therefore representing a potentially confounding factor if analyzed conjointly 
with patients without prior local irradiation.
CONCLUSIONS
Routine utilization of sirolimus-eluting stent implantation to treat in-stent restenosis appeared 
safe and effective in an unselected series of cases of in-stent restenosis, especially in patients 
with focal lesions. Sirolimus-eluting stent implantation also seems to be a promising strategy for 
complex in-stent restenosis. Further analysis with larger series and more prolonged follow-up, 
as well as a direct comparison with brachytherapy in a randomized fashion are needed to clarify 
the role of sirolimus-eluting stents in this context.
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FIGURE LEGEND
 
 
Figure 1. 
Sirolimus-eluting stent implantation for total occlusion due to in-stent restenosis: representative sequences of angiograms 
from two patients. patient 1. A. Diagnostic angiogram showing total occlusion of the proximal right coronary artery due to 
ISR (arrows). B. Final result after implantation of two overlapping SES, 3x18 mm proximal (1), and 3x33 mm distal (2). Some 
minimal residual stenosis is visible at the distal stent edge. C. Six-month angiographic follow-up showing persistence of the 
good result obtained previously. patient 2. A’. Diagnostic angiogram showing in-stent restenosis giving total occlusion of the 
mid part of the left anterior descending artery (LAD) (arrows), immediately after the origin of the second diagonal branch. B’. 
Final result after implantation of three overlapping SES in the LAD, 2.75x8 mm proximal (3), 2.5x33 mm in the middle (4), and 
2.25x8 mm distal (5). Bifurcation stenting was necessary to preserve the second diagonal (6, SES 2.25x8 mm). C’. Six-month 
angiographic follow-up showing persistence of the good result in both vessels.
Figure 2. 
Cumulative distribution of late loss at angiographic follow-up. Lesions with binary restenosis are indicated by empty squares. 
Clinical outcome of each restenotic lesion is reported corresponding to the respective late loss value. This curve resembles a 
bimodal distribution and suggests that the failures cases might share unique features.
A B C
A’ B’ C’
1
2
3
4
5
6
Figure 1
0%
20%
40%
60%
80%
100%
-1.00 -0.50 0.00 0.50 1.00 1.50 2.00 2.50 3.00
Lesions with restenosis
mm
Figure 2
TLR
TLR TLR
TLR
TLRTO, Med tx
28
Chapter 2
TABLES
Table 1. Baseline patient characteristics 
patients 44
Age, years±SD 63±13
Men 73%
Risk Factors  
 Current smoker 27%
 Hypercholesterolemia* 68%
 Systemic hypertension 48%
 Diabetes mellitus 25%
 Family history of coronary heart disease 43%
Clinical presentation
 Silent ischemia 9%
 Stable angina pectoris 64%
 Unstable angina pectoris 25%
 Acute myocardial infarction 2%
Multivessel coronary disease 50%
previous myocardial infarction 52%
previous coronary bypass 23%
Recurrent episodes of in-stent restenosis (>1) 25%
*Total cholesterol > 200mg/dl and/or on lipid lowering treatment
Table 2. Angiographic and procedural characteristics
Lesions 53
Target coronary artery
 Left anterior descending 49%
 Left circumflex artery 11%
 Right coronary artery 26%
 Left main 2%
 Saphenous vein graft 9%
 Left internal mammary artery 2%
Mehran class
 I (Focal) 42%
 II (Diffuse) 21%
 III (proliferative) 26%
 Iv (Total occlusion) 11%
Small vessel size* 49%
Bifurcation stenting† 18%
Multivessel stenting† 25%
Glycoprotein IIb/IIIa inhibitors† 9%
Stent length per lesion, mm 28 ± 20
Stents per patient, n 2.0 ± 1.4
*pre-procedure reference diameter ≤ 2.5 mm
†percentages relative to the number of patients
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Table 3. Quantitative angiographic analysis at baseline, post-procedure and follow-up*.
pre-procedure post-procedure Follow-up
Reference diameter, mm 2.64±0.56 2.73±0.54 2.83±0.50
Minimum lumen diameter, mm 0.90±0.55 2.33±0.59 2.20±0.81
Diameter stenosis, % 66±19 16±15 23±25
Lesion length, mm 17.5±12.1 - -
Acute gain, mm - 1.42±0.70 -
Late loss, mm - - 0.17±0.76
Late loss excluding occlusions, mm - - 0.11±0.67
Binary post-SES restenosis†, % 14.6
SES=sirolimus-eluting stent
*related to 41 lesions with angiographic follow-up
†including one total re-occlusion
Table 4. Binary post-SES restenosis in subgroups*
post-SES restenosis
Total population (n=41) 14.6 %
Diabetics (n=8) 25.0 %
Small vessel size (n=20) † 10.0 %
vein grafts (n=5) 20.0 %
Lesion length > 20mm (n=14) 28.6 %
Bifurcating stents‡ (n=7) 14.3 %
Mehran class2
 Type I (n=15) 0
 Type II (n=9) 22.2 %
 Type III (n=12) 25.0 %
 Type Iv (n=5) 20.0 %
Between brackets are reported the numbers of lesions with angiographic follow-up
* related to 41 lesions with angiographic follow-up
† pre-procedure reference diameter ≤ 2.5 mm
‡ this datum refers only to the in-stent restenosis lesions; in these series, there was no case of restenosis in the side-
branches treated for de novo lesions.
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ABSTRACT
Purpose: To compare the mid-term clinical outcome of sirolimus-eluting stent (SES) implantation 
and vascular brachytherapy (VBT) for in-stent restenosis (ISR).
Methods: We assessed the 9-month occurrence of major adverse cardiac events (MACE) in 
44 consecutive patients with ISR treated with SES implantation, and 43 consecutive patients 
treated with VBT in the period immediately prior.
Results: Baseline clinical and angiographic characteristics of the two groups were similar. 
During follow-up, 3 patients (7%) died in the VBT group and 0 in the SES group. The incidence 
of myocardial infarction was 2.3% in both groups. Target lesion revascularization was performed 
in 11.6% of the VBT patients and 16.3% of the SES patients (p=NS). The 9-month MACE-free 
survival was similar in both groups (79.1% VBT vs 81.5% SES; p=0.8 by log rank).
Conclusions: The result of this non-randomized study suggests that sirolimus-eluting stent 
implantation is at least as effective as vascular brachytherapy in the treatment of in-stent 
restenosis.
Keywords: sirolimus, eluting-stent, in-stent restenosis
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INTRODUCTION
In-stent restenosis (ISR) represents the major limitation of coronary stenting (1). Treatment 
of ISR with conventional strategies is limited by the high rate of recurrence, which gradually 
increase from focal lesions to proliferative patterns and total occlusions (2).
The “mechanical” approach to treat ISR, with utilization of additional stents or debulking devices, 
has failed to show substantial benefits (3-6). Vascular brachytherapy (VBT), by targeting the 
“biological” component of neointimal proliferation, is the only strategy proven to be effective 
in randomized trials (7-11). However, its utilization is limited by complex logistic requirements 
and the necessity of highly trained operators. Moreover, recurrent restenosis still occurs in 
approximately one third of the patients treated with vascular brachytherapy (7-11).
Sirolimus- (12-13) and paclitaxel-eluting stents (14) have been shown in randomized trials 
to strongly suppress the development of neointimal hyperplasia in selected de novo lesions 
compared to bare stents. Also, promising results have been recently reported with drug-eluting 
stents for the treatment of in-stent restenosis, especially for patients with less complex forms of 
restenosis (15-17). A relatively low incidence of repeat restenosis has been shown after drug-
eluting stent implantation in these preliminary series of cases. However, to date, the clinical 
efficacy of this new therapeutic approach has not been compared to conventional percutaneous 
techniches or to the “gold standard” vascular brachytherapy.
In this study we therefore aimed to comparatively evaluate the outcomes of patients with 
in-stent restenosis treated with sirolimus-eluting stent implantation or with catheter-based 
brachytherapy.
METHODS
patient population
Since the 16th of April 2002, we have adopted a policy of sirolimus-eluting stent implantation 
for all patients undergoing percutaneous coronary interventions at our institution, as previously 
described elsewhere (18). In the first six months enrollment, 44 consecutive patients with 
in-stent restenosis and no previous brachytherapy at the same site were treated with SES 
implantation (SES group). A comparison group was composed by 43 patients treated with 
vascular brachytherapy (group VBT) in the months immediately prior, between 1st January 2001 
and 15th of april 2002. This time period was selected to approximately match the number of 
patients with brachytherapy with the number of patients treated with sirolimus-eluting stent. 
All patients treated with both modalities were included in the present report. Informed, written 
consent was obtained from all patients.
procedures
All patients were pre-treated with aspirin (at least 75 mg/d) and clopidogrel (75 mg/d or 300 mg 
bolus). During the procedure weight-adjusted heparin was administrated to achieve an activated 
clotting time of >300 sec. Vascular brachytherapy was performed in all patients with catheter-
delivered beta-radiation. Two systems were used during the study period: BetacathTM (Novoste, 
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Norcross, GA), and GalileoTM (Guidant corporation, Santa Clara, CA, USA), which have been 
described in detail elsewhere (11, 19). Operators were strongly advised to avoid implantation 
of new stents (20), and to avoid insufficient radiation dose delivery to injured areas (geographic 
miss) (21). Clopidogrel prescription was decided on an individual patient basis by the attending 
interventional cardiologist according to current practice guidelines. In the SES group, restenotic 
lesions were treated with implantation of the CypherTM sirolimus-eluting stent (Cordis Europa 
NV, Roden, NL). Complete lesion coverage by this stent was recommended. In case additional 
stents were needed, care was taken to avoid gaps between adjacent stents. The final treatment 
strategy and device utilization other than SES were left to the operator’s discretion. At least 3 
months of clopidogrel treatment was prescribed thereafter. In both study periods, periprocedural 
adjunctive medications were left to the discretion of the operator.
Definitions and follow-up
ISR was defined as a significant stenosis within a previous stented segment on visual 
assessment, together with objective evidence of ischemia. The lesions were angiographically 
classified according to Mehran et al. (2) by two independent operators. The primary composite 
endpoint was the incidence of major adverse cardiovascular events (MACE) during 9 months 
of follow-up, defined as death, myocardial infarction or target lesion revascularization (either 
percutaneous or surgical). The diagnosis of myocardial infarction was based on an increased 
level of creatine kinase to more than twice the upper limit of normal with an increased level of 
creatine kinase-MB isoform. Target lesion revascularization (TLR) was defined, for the patients 
in the brachytherapy group, as any surgical or percutaneous re-intervention due to restenosis 
within the irradiated segment or the 5mm proximal or distal segments, and for the patients 
in the SES group as any revascularization in the stent and in the 5 mm proximal and distal 
segments. Target vessel revascularization (TVR) was defined as any re-intervention driven by 
lesions located in the treated vessel beyond the target lesion limits. Survival status at follow-up 
was assessed by written inquires to the Municipal Civil Registries. Repeat revascularization 
procedures and episodes of acute myocardial infarction were prospectively collected in the 
hospital data base. For patients admitted to peripheral hospitals in the acute phase, the 
diagnosis of myocardial infarction was confirmed by the referring physician based on the same 
criteria. All re-interventions were prospectively collected in a dedicated electronic database.
Statistical methods
Discrete variables were presented as count and relative percentages and compared with 
Fisher exact tests or Chi-square. Continuous variables were presented as mean and standard 
deviations and compared with Student t test. Event-free survivals were calculated according to 
the Kaplan-Meier method and compared by the log-rank test. All tests were two-tailed, and a p 
value <0.05 was considered as significant.
RESULTS
Baseline characteristics
The baseline characteristics of the two groups were similar (table 1). Specifically, no difference 
was observed in the incidence of diabetes ( 26% VBT vs 25% SES; p=0.1), previous myocardial 
infarction (47% VBT vs 52% SES; p=0.6), previous coronary artery bypass graft (CABG) surgery 
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(21% VBT vs 23% SES; p=0.8), or multivessel disease (47% VBT vs 50% SES; p=0.7). The 
majority of the patients in both groups had stable angina at hospital admission (79% VBT vs 
73% SES; p=0.5). Almost all patients in the VBT group had single-lesion brachytherapy, except 
by one patient with 2 lesions treated. In the SES group, 53 ISR lesions were treated (1.2 ± 
0.5 lesion per patient). In the SES group there were more lesions classified as Mehran type 
I (23% VBT vs 42% SES; p=0.05), whilst type II was more common in the VBT group (43% 
VBT vs 21% SES; p=0.02). However, both treatment groups had similar numbers of lesions 
with non-complex (Mehran Type I/II: 66% VBT vs 63% SES) or complex (Mehran Type III/IV: 
34% VBT vs 37% SES; p=0.7 for all) morphologies. Quantitative coronary analysis did not 
show significant differences in baseline lesions’ characteristics between the two groups (table 
2). Average lesion length was 15.7±10.4 mm in the VBT group and 17.5±12.1 mm in the SES 
group (p=0.4). As expected, post-procedure minimal lumen diameter was bigger (1.84±0.41 
mm VBT vs 2.33±0.59 mm SES; p=0.0008) and diameter stenosis smaller (28±12 % VBT vs 
16±15 % SES; p=0.004) in the SES group.
In the VBT group average irradiated length was 48 ± 12mm, and average radiation dose 
administered was 23 ± 2 Gy. A new stent was implanted in 27% of the VBT patients. In the SES 
group each patient received on average 2.0 ± 1.4 stents, with a mean stent length of 28 ± 20 
mm per lesion. In the VBT group periprocedural glycoprotein IIb/IIIa inhibitors utilization was 
more common (33% vs 9%; p=0.007), and clopidogrel prescription longer (7.5±5.5 months vs 
5.9±2.6 months; p=0.005).
Clinical outcome
Complete information at follow-up was available in 100% of VBT patients and 97.7% of SES 
patients (1 patient moved abroad and was lost to follow-up). During nine months of follow-up, 3 
patients (7%) died in the VBT group and 0 in the SES group (p=0.08 by log rank)(table 3). They 
were all thought to be cardiac deaths: one patient with previous CABG operation developed 
severe hypotension after balloon angioplasty and irradiation of the right coronary artery and 
died 2 days after the procedure; two patients had a sudden death 3 months after treatment of 
a lesion in the proximal left anterior descending while still on combined antiplatelet treatment 
(one of them had a new stent implanted during the brachytherapy procedure). Subacute stent 
thrombosis could not be ruled out in these last 2 cases. A definite diagnosis of acute MI was 
made in 1 patient in each group. Target lesion revascularization was performed in 5 patients 
(11.6%) in the VBT group, and 7 patients (16.3%) in the SES group (p=NS). In the VBT group 
these recurrent restenosis were treated with 2 CABG operations, 1 balloon angioplasty, 1 stent 
implantation, and 1 sirolimus-eluting stent implantation. In the SES group 1 patient underwent 
emergency CABG surgery for vessel dissection and acute occlusion during treatment of a 
lesion in the proximal left circumflex artery, and the remaining 6 TLRs were accomplished 
percutaneously (3 with additional SES implantation, 3 with taxol-eluting stent implantation). 
Overall, the MACE-free survival at 9 months was similar in both groups (79.1% VBT vs 81.5% 
SES; p=0.8 by log rank) (figure 1).
DISCUSSION
Vascular brachytherapy has been rigthly considered the gold-standard treatment for in-stent 
restenosis, at the least for more complex cases, after several randomized trials have shown 
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its superiority over other conventional approaches (7-11). Despite these favorable results, 
brachytherapy has not been widely utilized, being still currently restricted, at least in Europe, 
to a limited number of centers. Complex logistic and technical requirements, as well as lack of 
reimbursement in some countries, have limited a more generalized utilization of brachytherapy. 
Furthermore, the identification of possible shortcomings such as geographical miss (21) and 
delayed re-endothelialization, which is associated with an increased risk of subacute thrombosis 
especially when a new stent is implanted (22), have made mandatory a specific training for the 
operators involved in brachytherapy procedures.
In the present study, treatment of in-stent restenosis with sirolimus-eluting stents was 
associated with similar clinical results at 9 months compared to vascular brachytherapy. These 
findings are of potential major interest. Routine utilization of sirolimus-eluting stent implantation 
does not deviate from the standard practice with conventional bare stents. Indeed, no additional 
requirements are needed to readily apply this new therapy at any catheterization laboratory.
Widespread utilization of drug-eluting stents is expected to change the current scenario, 
by reducing ISR to a minority of patients. (12,23) Moreover, recurrent restenosis after drug-
eluting stent implantation presents peculiar characteristics, such as predominantly focal pattern, 
(24,25) which could improve its response to the various percutaneous treatments. However, 
despite the enthusiasm raised by the publication of the first clinical studies, drug-eluting stent 
penetration in common practice is still limited by cost restrains (26), and ISR remains the major 
limitation of PCI. In this early drug-eluting stents era, “provisional” SES utilization in case of bare 
stent failure is appealing and, based on the results of the present study and two prior reports 
(15,16), seems to be a feasible and effective strategy.
In the evaluation of our results, two additional pieces of information should be taken into 
account. Although not statistically significant, a slightly higher rate of TLR was observed in the 
SES group. However, in this group routine angiographic follow-up was scheduled by protocol, 
and performed in 77% of the patients, while only a minority of patients in the VBT group underwent 
elective angiography (30%). We have previously shown that angiographic follow-up have a 
negative impact on clinical outcome due to more repeat revascularization procedures (“oculo-
stenotic reflex”) (27). Furthermore, a late “catch-up” phenomenon (continuous increasing of 
angiographic late-loss after 6 months) has been reported for VBT (28,29), while data regarding 
SES for both de novo (30) and ISR (16) lesions suggest that the early results are predictive of 
the long-term findings. On the other hand, although not statistically significant, we observed an 
increased mortality in the brachytherapy group (VBT: 7%; SES: 0%; p=0.08), suggesting once 
again the possibility of serious adverse events related to the prolonged endothelial damage 
after vessel irradiation. 
 
Study limitations
Our study presents a number of limitations that suggest some caution when interpreting the 
results. First of all, the two groups were not randomized, and were treated in different time 
periods. Moreover, while the SES group was composed of a consecutive series of patients, 
the patients undergoing VBT group were selected by the operators based on clinical and 
morphological consideration. Accordingly, more patients in the SES group presented Mehran 
type I lesions (23% VBT vs 42% SES), because in the VBT phase most of these patients 
underwent percutaneous re-intervention with conventional techniques. However, we cannot 
ignore the fact that baseline clinical characteristics of the 2 cohorts of patients were remarkably 
similar. Additionally, if we consider together lesions of Mehran class I and II, the difference among 
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the two groups disappears (66% VBT vs 63% SES; p=0.7). This was indirectly confirmed by the 
lack of difference in lesion length between the two groups. Other imbalances were observed 
in procedural characteristics and peri-procedural medications. The higher rate of glycoprotein 
IIb/IIIa inhibitors in the VBT-treated patients, and the longer clopidogrel prescription in the same 
group, could have generated a clinical advantage, especially in those with acute coronary 
syndromes (31,32). More lesions were treated per patient in the SES group; while on one 
side this strategy could favour recurrent restenosis and repeat revascularizations, especially 
in patients with angiographic follow-up, on the other side a possible positive impact of a more 
complete revascularization on clinical outcome cannot be ruled out. 
Another limitation is represented by the low number of patients in both groups. It should be 
noticed, however, that the present study is, to the best of our knowledge, the first comparison 
between VBT and SES in the treatment of ISR, and in this setting the study which included 
the higher number of patients treated with SES reported so far (15,16). Moreover, the first 
randomized trial comparing vascular brachytherapy with conventional balloon dilatation included 
only 55 patients (8).
CONCLUSIONS
In this study, routine sirolimus-eluting stent implantation to treat in-stent restenosis appeared 
at least as effective as vascular brachytherapy in the treatment of in-stent restenosis, with 
the advantage of simpler logistic and technical requirements. Further prospective, randomized 
investigation with larger study population and longer follow-up are mandatory to confirm these 
findings.
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Figure 1. kaplan-Meier curves of survival-free from major adverse cardiac events (MACE) in the 
brachytherapy (vBT) and in the sirolimus-eluting stent (SES) groups.
Figure 1
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Table 1. Baseline clinical characteristics and demographics of the two study cohorts.
vBT
(n. 43)
SES
(n. 44) p value
Age, y 61±10 63±13 ns
Males, n (%) 31 (73) 32 (73) ns
Diabetes Mellitus, n (%) 11 (26) 11 (25) ns
Hypertension, n (%) 13 (30) 21 (48) ns
Hypercholesterolemia, n (%) 26 (60) 30 (68) ns
previous MI, n (%) 20 (47) 23 (52) ns
previous CABG, n (%) 9 (21) 10 (23) ns
Multivessel disease, n (%) 20 (47) 22 (50) ns
Clinical presentation, n (%)
 Stable Angina
 ACS
34 (79)
9 (21)
32 (73)
12 (27)
ns
Number of ISR lesions treated 44 53 -
ISR lesions treated per patient 1.0 ± 0.2 1.2 ± 0.5 0.02
Target vessel, n (%)
 LAD
 LCX
 RCA
 LM
 Bypass grafts 
16 (36)
9 (20)
15 (34)
1 (2)
3 (7)
26 (49)
6 (11)
14 (26)
1 (2)
6 (11)
ns
Mehran classification, n (%)
 Type I
 Type II
 Type III
 Type Iv
10 (23)
19 (43)
10 (23)
5 (11)
22 (42)
11 (21)
14 (26)
6 (11)
0.05
0.02
ns
ns
Multivessel procedure, n (%) 9 (21) 11 (25) ns
procedural success*, n (%) 42 (98) 43 (98) ns
IIb/IIIa inhibitors, n (%) 14 (33) 4 (9) 0.007
Clopidogrel prescription, mo 7.5 ± 5.5 5.9 ± 2.6 0.005
ACS=Acute Coronary syndromes; CABG=Coronary Artery Bypass Graft; LAD=left anterior descending artery; LCX=left 
circumflex artery; MI=Myocardial Infarction; RCA=right coronary artery; LM=left main stem; TL=Target Lesion
*as judged by the operator, in the absence of in-hospital complications.
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Table 2. Quantitative coronary analysis at baseline
vBT
(n. 44)
SES
(n. 53) p value
pre-procedure
 Reference diameter, mm 2.44 ± 0.45 2.64 ± 0.56 ns
 MLD, mm 0.74 ± 0.52 0.90 ± 0.55 ns
 Diameter stenosis, % 69 ± 20 66 ± 19 ns
 Lesion length, mm 15.7 ± 10.4 17.5 ± 12.1 ns
post-procedure
 Reference diameter, mm 2.61 ± 0.51 2.73 ± 0.54 ns
 MLD, mm 1.84 ± 0.41 2.33 ± 0.59 0.0008
 Diameter stenosis, % 28 ± 12 16 ± 15 0.004
MLD = Minimal Lumen Diameter 
Table 3. Nine-month clinical outcome
vBT
(n. 43)
SES
(n. 44)
All MACE, % 20.9 18.6
Death, % 7.0 0
Myocardial infarction, % 2.3 2.3
Target Lesion Revascularization, % 11.6 16.3
Target vessel Revascularization, % 4.7 4.7
Coronary bypass graft, % 7.0 2.3
percutaneous coronary intervention, % 9.3 18.6
MACE=Major Adverse Cardiovascular Events
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Effectiveness of Sirolimus-Eluting Stent Implantation
for Recurrent In-Stent Restenosis After Brachytherapy
Francesco Saia, MD, Pedro A. Lemos, MD, Georgios Sianos, MD,
Muzaffer Degertekin, MD, Chi-Hang Lee, MD, Chourmouzios A. Arampatzis, MD,
Angela Hoye, MD, Kengo Tanabe, MD, Evelyn Regar, MD, PhD,
Willem J. van der Giessen, MD, PhD, Pieter C. Smits, MD, PhD, Pim de Feyter, MD, PhD,
Jurghen Ligthart, MSc, Ron T. van Domburg, MSc, PhD, and Patrick W. Serruys, MD, PhD
Coronary vascular brachytherapy is, to date, theonly effective treatment available for complex in-
stent restenosis (ISR).1 However, its efficacy is ham-
pered by late restenosis,2 late thrombosis,3,4 edge ef-
fect,5 geographic miss,6 and delayed healing.3 More-
over, the fate of the patients after “failed” brachytherapy
is uncertain, as well as the result of the various percuta-
neous treatments employed thereafter. Sirolimus is a
macrolide antibiotic produced by Streptomyces hygro-
scopicus with immunosuppressive effects; it is approved
for the prevention of renal transplant rejection.7 The
main effect of sirolimus is the interruption of G1 to S cell
cycle progression mediated by its binding to a cytosolic
receptor (FK506 protein binding protein 12) and a cas-
cade of subsequent actions. Importantly, sirolimus inhib-
its proliferation and migration of vascular smooth muscle
cells, a key element in the development of restenosis
after percutaneous coronary interventions (PCIs). Re-
cently, stent-based local sirolimus delivery has been
shown to strongly suppress neointimal hyperplasia and
prevent restenosis in de novo lesions followed up for 2
years.8,9 The revolutionary results obtained with drug-
eluting stents have encouraged the assessment of their
efficacy in more complex clinical and morphologic sub-
sets. The first human experience evaluating the siroli-
mus-eluting stent (SES) for the treatment of ISR has
been recently reported; it showed this strategy to be
highly effective.10 We describe here the first series of
patients treated with SESs for recurrent ISR after brachy-
therapy.
• • •
The patients described in this report consist of 2
cohorts treated during separate time periods. The first
cohort was treated between March 2001 and June
2001, as part of a pilot study on SESs for treatment of
ISR. Since April 2002, shortly after European Com-
munity market approval, SES implantation has been
adopted as the default strategy in all patients treated
with PCI at our institution, irrespective of clinical
presentation and coronary morphology. These latter
patients have been included in the RESEARCH Reg-
istry (Rapamycin-Eluting Stent Evaluated At Rotter-
dam Cardiology Hospitals) and will be followed up
for 1 year.11 The only exclusion criteria were unavail-
ability of an adequately sized SES at the time of the
procedure and enrollment in another revascularization
protocol (SESs were available in diameters from 2.25
to 3.0 mm and lengths of 8, 18, and 33 mm). All
patients treated with SES after “failed” brachytherapy
were scheduled for 6-month angiography.
ISR was defined as 50% diameter stenosis by
quantitative coronary angiography within a previously
stented vessel segment and classified as proposed by
Mehran et al.12 Treatment strategy and device utiliza-
tion other than stenting was left to the physician’s
discretion. The procedure was considered successful
when residual stenosis 30% by quantitative coro-
nary angiography was achieved together with Throm-
bolysis In Myocardial Infarction (TIMI) flow grade 2
to 3. The study stent utilized was the sirolimus-eluting
Cypher (Cordis Europa NV, Johnson & Johnson, Ro-
den, The Netherlands), which contains a 140 g siroli-
mus/cm2 metal surface area in a slow release formu-
lation (28 days). Pretreatment with clopidogrel for
48 hours or a 300-mg loading dose was required.
During the procedure, intravenous heparin was given
to maintain an activated clotting time 300 seconds.
After the procedure, all patients received aspirin in-
definitely (75 mg/day) and clopidogrel (75 mg/day)
for at least 2 months. Clinical status information was
collected at follow-up visits or by telephone contact
with the patient or referring physician. Data are pre-
sented as number and relative percentage or mean 
SD. Median and range have been reported when
deemed necessary for a better description.
From the beginning of the study until August 15,
2002, 12 consecutive patients (both cohorts) under-
went PCI with SES implantation for recurrent ISR
after local radiation therapy. All of them presented
with angina pectoris and/or myocardial ischemia as
documented by stress test or thallium scan. Coronary
brachytherapy had been previously performed in 11
patients with catheter-based local irradiation (10 beta,
1 gamma) and in 1 patient with phosphorus-32 radio-
active stent implantation.
Baseline clinical and angiographic characteristics
are listed in Tables 1 and 2, respectively.
Nine patients (75%) had had more than 1 previous
episode of restenosis. Average time from the preced-
ing percutaneous reintervention was 24 months (range
111 to 1,678 days, median 719).
Remarkably, 9 patients (75%) presented with a
From Erasmus MC, Thoraxcenter, Rotterdam, The Netherlands. Dr.
Serruys’ address is: Erasmus MC, Thoraxcenter, Bd404, Dr. Molewa-
terplein 40, 3015 GD Rotterdam, The Netherlands. E-mail: p.w.j.
c.serruys@erasmusmc.nl. Manuscript received January 16, 2003; re-
vised manuscript received and accepted April 14, 2003.
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proliferative pattern of restenosis, 5 of whom (42%)
had a totally occluded target vessel. The occlusion
dated more than 3 months in 4 patients.
Overall, we implanted 18 SESs (average 1.5/pa-
tient). Mean stent length was 33.9  30.1 mm (range
8 to 92; median 18), and mean stent diameter was 2.88
 0.33 mm. Multivessel PCI was performed in 3
patients (25%).
Angiographic success was obtained in 11 of 12
patients (92%). The remaining patient showed a 34%
residual stenosis during quantitative coronary angiog-
raphy and stent underexpansion despite very high-
pressure inflation (24 atm). Individual clinical out-
comes are listed in Table 3. With the obvious excep-
tion of the single patient presenting with acute
TABLE 1 Patients’ Baseline Characteristics and Demographics
Patients 12
Age (yrs) 62  11
Men 9 (75%)
Current smoker 4 (33%)
Hypercholesterolemia* 11 (92%)
Systemic hypertension 6 (50%)
Diabetes mellitus 3 (25%)
Family history of coronary
heart disease
4 (33%)
Stable angina pectoris 7 (58%)
Unstable angina pectoris 4 (33%)
Acute myocardial infarction 1 (8%)
Multivessel coronary disease 10 (83%)
Previous myocardial infarction 9 (75%)
Previous coronary bypass 4 (33%)
Time from last target lesion
revascularization (d)
111–1,678 (719)
Time from brachytherapy (d) 111–1,968 (792)
Episodes of ISR
1 9 (75%)
2 5 (42%)
*Total cholesterol 200mg/dl and/or receiving lipid lowering treatment.
Values expressed as mean  SD, range (median), or as number of patients
(%).
TABLE 2 Angiographic and Procedural Characteristics
Variable
Target coronary artery
Left anterior descending 2 (17%)
Left circumflex artery 5 (42%)
Right 4 (33%)
Left main 1 (8%)
Quantitative coronary analysis, before procedure
Reference diameter (mm) 2.83  0.48
Minimum lumen diameter (mm) 0.67  0.76
Diameter stenosis (%) 77  25
Quantitative coronary analysis, after procedure
Reference diameter (mm) 2.76  0.38
Minimum lumen diameter (mm) 2.38  0.45
Diameter stenosis (%) 13  11
Acute gain (mm) 1.71  0.58
Late loss (mm) 0.68  1.20
Multivessel coronary procedure 3 (25%)
Other devices utilized
Cutting balloon 3 (33%)
Cross Safe* 1 (8%)
Values expressed as mean  SD or number (%).
*Intraluminal Therapeutics Inc., Carlsbad, California.
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myocardial infarction, no postprocedural cardiac en-
zyme elevation was observed, and all the patients
were discharged home free from events.
Average follow-up was 8.5  4.5 months. Ten
patients (83%) underwent angiography between 4 and
7 months after the procedure. Two patients who re-
fused angiographic follow-up were asymptomatic af-
ter 4 and 6 months. One patient died after 9.5 months
because of congestive heart failure, shortly after hos-
pital admission for acute pulmonary edema. He was
79 years old, with a history of 2 coronary artery
bypass graft operations and 2 PCIs. Left ventricular
dysfunction and end-stage congestive heart failure
were diagnosed before the last coronary angioplasty.
During the 4-month follow-up, no intravascular ultra-
sound evidence of neointimal hyperplasia was found.
Recurrent ISR after SES implantation was found in
4 out of 10 patients who underwent angiography dur-
ing follow-up (40%). One of them, in whom complete
stent expansion could not be achieved at index proce-
dure, was found to have silent reocclusion after 4
months. No further treatment was performed, and at
19 months the patient remained asymptomatic. Two
other patients, both diabetics, presented with stable
angina (Canadian Cardiovascular Society class 3) and
ISR that required target lesion revascularization. In 1
of them, intravascular ultrasound showed a clearly
underexpanded stent with a very small minimal in-
stent diameter (1.3 mm). In the fourth case, a very
focal restenosis (5 mm) was diagnosed by elective
angiography 5 months after the procedure. Originally,
the patient had been treated with 4 SESs (overall
length 92 mm) for chronic total occlusion of the left
anterior descending artery (ISR). Intravascular ultra-
sound examination confirmed the absence of neointi-
mal hyperplasia in the remaining portion of the stents.
The patient was asymptomatic, but percutaneous re-
vascularization was performed based on intravascular
ultrasound findings.
Another patient had recurrent angina 4 months
after the procedure. Angiography showed minimal
in-stent hyperplasia in the region of interest, whereas
a severe lesion due to ISR requiring percutaneous
treatment was found in a different vessel.
One of the lesions treated with an SES during the
index procedure was composed of echolucent tissue
(“black hole”).13 Interestingly enough, the intravascu-
lar ultrasound examination at follow-up showed a
reappearance of this tissue, although it did not signif-
icantly affect the lumen area.
• • •
SESs have been recently shown to strongly prevent
the development of neointimal hyperplasia after stent-
ing. The first randomized clinical trial reported an
exceptional 0% binary restenosis rate.8 Whether a
similar result is obtainable in different clinical situa-
tions and for more complex coronary lesion subsets is
the subject of extensive investigation. Preliminary re-
sults for their use in the treatment of ISR are positive,
although less impressive than in de novo lesions.10
In the present investigation, we sought to assess the
safety and outcome of SES implantation in patients
with recurrent ISR after brachytherapy. The strategy
evaluated is safe and is believed to be clinically ef-
fective, considering the complex population under in-
vestigation. The 0% incidence of in-hospital events as
well as the absence of subacute stent thrombosis is
noteworthy because the average stent length was re-
markably high, and these patients are likely to have
endothelial dysfunction. The only death that occurred
is highly unlikely to be related to either the procedure
or to the stent, but rather to the severely compromised
left ventricular function. Nevertheless, our report
raises a series of unresolved issues. The antiprolifera-
tive effect of sirolimus after brachytherapy seems to
be strongly reduced compared with other situations.
The 40% incidence of restenosis in our population is
noteworthy. Diabetes mellitus, a well-known risk fac-
tor for restenosis, may also represent a predisposing
factor for failure in this setting. However, in 2 cases,
technical causes of failure (stent underexpansion)
could be implicated, and in a third patient, a very focal
neointimal growth was observed compared with the
very long baseline lesion and total stent length. The
optimal duration of combined antiplatelet therapy is
unclear. In this series there was a striking variety in
the duration of clopidogrel prescribed after the proce-
dure due to decisions made on an individual patient
basis. Currently, we prescribe combined antiplatelet
therapy for 12 months or lifelong after very long stent
implantation, but this approach deserves further eval-
uation.
Our investigation presents a few limitations. First,
we do not have a control population. Whether a con-
ventional approach would have provided comparable
results cannot be inferred from our data. Second, the
present series of patients is quite heterogenous; this is
not surprising given the “real world” setting. The time
elapsed from the last target vessel revascularization
was considerably different among patients. The un-
derlying physiopathologic process of late (around 2
years) recurrent restenosis after brachytherapy and
subsequent response to treatment is not known
(whether it is neointimal tissue or late atherosclerotic
progression is unclear). Moreover, the incidence of
black hole may be higher than suspected, and the
biologic properties of this tissue may be responsible
for a blunted response to antiproliferative drugs.
Last, but not least, the number of patients in our
investigation was low, and larger studies with ex-
tended follow-up are warranted to draw definitive
conclusions.
In this investigation, 12 patients were treated
with sirolimus-stent implantation for recurrent
ISR after failed brachytherapy. The strategy eval-
uated was safe and is believed to be clinically ef-
fective, although our data suggest a different atten-
uated efficacy of sirolimus in preventing neointimal
growth in this setting compared with the treatment
of de novo lesions.
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Prognostic Value of Corrected QT-Interval
Prolongation in Patients With Unstable
Angina Pectoris
Francisco L. Gadaleta, MD, Susana C. Llois, MD, Alberto R. Lapuente, MD,
Velislav N. Batchvarov, MD, and Juan C. Kaski, MD, DSc
The presence and magnitude of ST-segment devia-tion have independent predictive values for death
and nonfatal acute myocardial infarction (AMI) in
patients with unstable angina pectoris (UAP), in ad-
dition to their well-known diagnostic value.1 How-
ever, the prognostic importance of T-wave inversion
in UAP remains to be confirmed.2 Significantly less is
known about the prognostic value of QT-interval pro-
longation in patients with UAP. Abnormal prolonga-
tion of the heart rate corrected QT (QTc) interval
prolongation has been reported in patients with UAP,3
but its association with adverse outcomes in these
patients has not been investigated. However, QTc
prolongation is frequently observed in patients with
AMI4 –7 and is known to represent an established
risk factor in post-AMI patients.8 The present report
assesses whether QTc-interval prolongation is an
independent prognostic marker in patients with
UAP.
• • •
We studied 102 patients (68 men, mean age 57 
10 years, range 39 to 78) from a larger cohort of
patients (n  186) admitted to the Eva Pero´n General
Hospital, Buenos Aires, Argentina, between Septem-
ber 1995 and May 2000 with UAP diagnosed on
the basis of preestablished criteria.9 Patients with at
least one of the following were not included: post–
AMI angina pectoris (n  16), normal electrocar-
diogram (ECG) on admission (n  29), ECG with
excessive noise and/or flat (0.05 mV) T-waves
precluding QT-interval measurement (n  12), se-
rum potassium levels 3.5 mmol/ml (n  3), use of
antiarrhythmic drugs (n  3), complete bundle
branch block, Wolff-Parkinson-White syndrome, or
atrial fibrillation (n  3), evolving AMI as assessed
by serum creatine kinase (greater than twice the
normal limit) and its MB isoenzyme (5% normal
limit; n  4), and need for emergency interven-
tional therapy (n  14).
All patients were in Braunwald9 class II or IIIB and
had diagnostic changes on the standard 12-lead ECG
recorded during hospital admission (i.e., ST-segment
depression [n 26], T-wave inversion0.2 mV [n
54], transient ST-segment elevation [n  9], symmet-
ric and sharp positive T wave [n  3] and negative T
wave changing into positive [“pseudonormalization”;
n  10]).
Patients were subdivided into 2 groups according
to the presence (group A) or absence (group B) of
clinical events (i.e., death, new AMI, or newly estab-
lished indication for emergency percutaneous translu-
minal coronary angioplasty or coronary artery bypass
graft surgery during the coronary care unit stay and
30 days after hospital discharge). The consultant in
charge who was blinded to the results of QTc mea-
surements took clinical decisions regarding patient
management. Group A comprised 62 patients with
clinical events and group B 40 patients without clin-
ical events during the follow-up period. No investiga-
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Argentina; and the Department of Cardiological Sciences, St.
George’s Hospital Medical School, London, United Kingdom. Dr.
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Incidence of Thrombotic Stent Occlusion During the
First Three Months After Sirolimus-Eluting Stent
Implantation in 500 Consecutive Patients
Evelyn Regar, MD, PhD, Pedro A. Lemos, MD, Francesco Saia, MD,
Muzaffer Degertekin, MDd, Kengo Tanabe, MD, Chi-Hang Lee, MBBS, MRCP,
Chourmouzios A. Arampatzis, MD, Angela Hoye, MB, ChB, Georgios Sianos, MD,
Pim de Feyter, MD, PhD, Willem J. van der Giessen, MD, PhD, Peter C. Smits, MD, PhD,
Ron T. van Domburg, PhD, and Patrick W. Serruys, MD, PhD
Sirolimus-eluting stents have been used in our insti-
tution for all percutaneous interventions, without clin-
ical or anatomic exclusion criteria, as part of the
Rapamycin-Eluting Stent Evaluated At Rotterdam Car-
diology Hospital registry. We analyzed the incidence
of (sub)acute stent thrombosis after sirolimus-eluting
stent implantation in an unselected population of 510
consecutive patients. At 3-month follow-up, (sub-
)acute stent thrombosis was diagnosed in 2 patients
(0.4%) 6 hours and 11 days after the procedure,
respectively. These cases occurred in diabetic women
with complex coronary lesions. Intravascular ultra-
sound examination showed inadequate stent expan-
sion and uncovered distal dissection as possible me-
chanical explanations for the thrombosis. 2004
by Excerpta Medica, Inc.
(Am J Cardiol 2004;93:1271–1275)
S irolimus-eluting stents (SESs) have proved to sig-nificantly decrease restenosis in selected patients
with relatively simple lesions.1 This late benefit was
accomplished without compromising the well-estab-
lished low incidence of short-term complications with
currently available bare stents. Specifically, in these
studies, SESs have been associated with a low inci-
dence of stent thrombosis, a condition largely reported
to carry high risks of morbidity and mortality.2 How-
ever, these results cannot be directly extrapolated to
patients with more complex profiles, such as those
commonly treated in daily practice. After bare-metal
stent implantation, the incidence of sudden stent
thrombosis has been shown to increase in patients
with acute coronary syndromes, long stents, small
vessels, long-term total occlusion, and in those who
require multivessel intervention.3 We therefore inves-
tigated the incidence of (sub)acute stent thrombosis
(SAT) occurring in the first 3 months after the proce-
dure in an unselected cohort of consecutive patients
treated with SES implantation in our institution.
• • •
Since April 16, 2002, the SES (Cypher, Cordis
Corp., Johnson & Johnson, Warren, New Jersey) has
been used as the device of choice for all percutaneous
coronary interventions performed in our institution as
part of the Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospitals registry. The study
design has been described elsewhere.4 In brief, this is
a single-center registry with the main purpose of eval-
uating the effectiveness of SES implantation in pa-
tients treated in the “real world.” Therefore, SES has
been used in virtually all clinical situations and lesion
morphologies with no specific contraindications.
All procedures were performed according to stan-
dard techniques, and the final interventional strategy
was left to the discretion of the operators. At the
initiation of this study, SESs were available in diam-
eters from 2.25 to 3.00 mm and lengths of 8, 18, and
33 mm. Glycoprotein IIb/IIIa inhibitors were given at
the discretion of the operator, including situations
associated with high risk for SAT, such as acute
coronary syndromes, long stents, small vessels, long-
term total occlusion, and need for multivessel inter-
vention. All patients were on life-long aspirin admin-
istration and received a loading dose of clopidogrel
(300 mg), which was maintained for 3 months (75
mg/day).
Clinical follow-up at 3 months was performed by
scheduled visits at the outpatient clinic or by direct
contact (telephone or regular mail). Recordings of all
repeat interventions (surgical and percutaneous) and
rehospitalizations were prospectively collected in a
dedicated database. Survival status at 30 days was
assessed by written inquiries to the municipal civil
registries. The local ethical committee approved the
study, and written informed consent was obtained
from all patients.
Thrombotic stent occlusion was documented an-
giographically as a complete occlusion (Thrombolysis
In Myocardial Infarction [TIMI] flow 0 or 1) or as a
flow-limiting thrombus (TIMI flow 1 or 2) of a suc-
cessfully treated artery (TIMI flow 3 immediately
after stent placement and percent in-lesion diameter
stenosis30%). Acute occlusion was defined to occur
at24 hours, subacute occlusion was defined to occur
at 24 hours to 30 days after the study procedure,
and late occlusion was defined to occur30 days after
the index procedure. Discrete variables were pre-
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sented as counts and percentages, and continuous vari-
ables were expressed as mean  1 SD.
Between April 16 and September 17, 2002, 510
consecutive patients (842 lesions) were treated with
1,093 SESs(2.1  1.3 SESsper patient). Baseline
characteristics are listed in Table 1. Overall, 15.7% of
patients had acute myocardial infarction and 32.4%
had unstable angina at admission. Multivessel stent
implantation was performed in 25%, nominally small-
diameter stents (2.5 or 2.25 mm) were implanted in
25.7%, and a long-stented segment (36 mm) was
recorded in 17.5%. Glycoprotein IIb/IIIa inhibitors
were used in 24% of cases.
Clinical 3-month follow-up information was ob-
tained in all patients. Duringthe first 3 months after
the procedure, 2 patients (0.4%) developed SAT (Fig-
ures 1 and 2). These patients were receiving aspirin
and clopidogrel at the time of the event.
• • •
In the present study, SAT occurred in 2 of 510
consecutive unselected patients treated with SESs.
The 0.4% incidence of SAT at 3 months observed in
our series is low and comparable to that reported for
conventional bare-metal stents.2,5 The patients with
stent thrombosis were women with diabetes and com-
plex coronary lesions. Intravascular ultrasound exam-
ination showed that mechanical factors may have pre-
disposed these patients to these complications
(inadequate stent expansion and uncovered distal dis-
section). This is correlated with recent findings in a
large series of bare-metal stents.6 SAT was found to
be related mainly to inadequate postprocedure lumen
dimensions or to procedure-related abnormal lesion
morphologies (dissection, thrombus, or tissue pro-
lapse). Stents in the left anterior descending artery
have been implicated more often than stents in other
vessels in stent thrombosis, but in that cohort the
diameters of the left anterior descending artery were
smaller than those in the right coronary artery.7
Although diabetes is a well-established predictor of
adverse outcome,8 the effect of gender is controver-
sial. In recent studies comparing the outcome for
women and men after with bare-metal stent implanta-
tion, a higher event rate,9 a lower event rate,10 or
similar event rates11 have been reported in women
versus men.
Combined oral antiplatelet therapy12 and system-
atic high-pressure stent implantation13 have decreased
the incidence of thrombotic occlusion after conven-
tional coronary stenting.14 Because SESshave virtu-
ally the same physical properties as bare-metal stents,
we used a similar approach to accomplish optimum
SESdeployment. In our series, the average implanta-
tion pressure was 17 atm, and balloon postdilatation
was performed in approximately half the cases. All
TABLE 1 Baseline and Procedural Characteristics (n  510)
Men (n  359) Women (n  151)
Age (yrs) 60.5  11.9 63.3  10.9
Diabetes mellitus 16.0% 23.7%
Current smoker 39.3% 32.6%
Systemic hypertension 40.9% 59.0%
Previous myocardial infarction 34.8% 22.8%
Previous percutaneous coronary intervention 26.5% 20.3%
Previous coronary bypass 10.1% 10.7%
No. of coronary arteries narrowed 50%
1 45.8% 45.9%
2 31.7% 25.7%
3 22.5% 28.4%
Stable angina pectoris 52.1% 51.7%
Unstable angina pectoris 31.5% 33.1%
Acute myocardial infarction 16.7% 13.9%
Glycoprotein IIb/IIIa inhibitors 27.9% 21.3%
Treated coronary artery*
Left main stem 3.7% 3.3%
Left anterior descending 57.4% 57.0%
Left circumflex 36.5% 29.8%
Right 34.3% 41.1%
Multivessel SES implantation 25.3% 23.2%
No. of SESs per procedure 2.1  1.3 stents 2.1  1.2 stents
Total length of the implanted stents (range) 38.0  26.9 mm/patient (8–152 mm) 37.9  26.5 mm/patient (8–184 mm)
Adjacent stented length 36 mm 17.5% 17.2%
Small-diameter stent (2.5 or 2.25 mm) 36.5% 33.9%
Postdilatation performed 56.6% 51.0%
Intravascular ultrasound use 20.6% 20.5%
Maximum pressure 17.2  2.6 atm 17.2  2.8 atm
Reference diameter 2.70  0.49mm 2.70  0.54mm
Minimal lumen diameter before SES 0.75  0.45mm 0.71  0.45mm
Diameter of stenosis before SES 71  17% 71  18%
Minimal lumen diameter after SES 2.31  0.49mm 2.35  0.46mm
Diameter of stenosis after SES 15  12% 14  9%
*Not mutually exclusive—in patients with multivessel disease, several arteries were treated.
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patients were maintained under dual antiplatelet treat-
ment.
Previous studies have suggested that sirolimus can
significantly enhance agonist-induced platelet aggre-
gation15 and impair endothelial function.16 Animal
models have shown focal remnants of residual fibrin
deposition adjacent to the struts, which may reflect a
delay in arterial repair or impaired fibrin degradation
secondary to the local effects of the drug.17 However,
although these features may increase the risk of
thrombotic complications, our findings suggest a min-
imal risk of SAT after SES implantation, even in
patients with well-known risk factors for short-term
thrombotic complications. Although similar SAT rates
have been reported in clinical trials with SES,1 the
present report allowed a comprehensive evaluation of
FIGURE 1. (A) Preintervention. Lesions in the distal (I) and middle (II) right coronary arteries (III). Lesions in the distal left anterior de-
scending artery (lesion length 6.91 mm; reference diameter 2.63 mm, minimal lumen diameter 1.58 mm) and the apical left anterior
descending artery (lesion length 9.82 mm, reference diameter 1.71 mm, minimal lumen diameter 0.89 mm). (B) After SES implanta-
tion in the distal left anterior descending artery (SES 3.0/8 and 2.25/18 mm at 12 atm, reference diameter 2.51 mm, minimal lumen
diameter 2.58 mm) and the apical left anterior descending artery (SES 2.25/8 mm at 10 atm, reference diameter 1.95 mm, minimal
lumen diameter 1.75 mm). (C) (I) Coronary angiography 6 hours after the index procedure shows total occlusion of the SES in the
apical left anterior descending artery (apart from the stents in the distal left anterior descending artery). Intravascular ultrasound
scans show underexpansion of the apical stent (III) (minimal stent area 2.00 mm2) compared with the proximal (II) (lumen area 3.81
mm2) and distal (IV) (lumen area 3.10 mm2) references and a distal edge dissection (V, arrows) that was not visible on the angio-
gram at the time of the index procedure.
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Usefulness of Myocardial Viability or Ischemia in
Predicting Long-Term Survival for Patients With
Severe Left Ventricular Dysfunction
Undergoing Revascularization
Lawrence Liao, MD, Christopher H. Cabell, MD, James G. Jollis, MD,
Eric J. Velazquez, MD, William T. Smith IV, MD, Kevin J. Anstrom, PhD,
Paul A. Pappas, MS, Thomas Ryan, MD, Joseph A. Kisslo, MD, and
Carolyn K. Landolfo, MD
In 107 patients with coronary disease and severe left
ventricular dysfunction, we examined the prognostic
power of viability identified by dobutamine stress
echocardiography. At a mean follow-up of 27
months, patients with viable myocardium who under-
went revascularization had a significant survival ad-
vantage over all other patients (2-year survival
83.5% vs 57.2%, p  0.0037). 2004 by Excerpta
Medica, Inc.
(Am J Cardiol 2004;93:1275–1279)
A lthough dobutamine stress echocardiography(DSE) can identify myocardial viability and pre-
dict improved outcomes, previous studies have in-
cluded patients with only mild or moderate left ven-
tricular dysfunction (ejection fraction 40%).1–3 No
DSE studies have specifically considered the long-
term value of viable myocardium in patients with
severely depressed left ventricular systolic function.
This high-risk cohort of patients has the greatest peri-
operative mortality but potentially stands to benefit the
most from revascularization.4,5 The purpose of this
study was to assess whether myocardial viability with
DSE would identify patients with severe left ventric-
ular systolic dysfunction who would benefit most from
revascularization.
• • •
The study population (n  107) consisted of pa-
tients who underwent DSE for viability assessment
and cardiac catheterization, documenting significant
coronary artery disease (1 diameter stenosis 75%
in a major epicardial coronary segment) within 90
days of DSE. The study sample was derived from
consecutive patients who underwent DSE and coro-
nary angiography from 1996 to 2001 at our institution.
Patients who underwent cardiac catheterization at our
institution were prospectively followed in the Duke
Cardiovascular Databank. The methods used by the
Cardiovascular Databank have been described previ-
ously.6,7 After their index catheterization, patients
were followed at 6 months and annually for mortality
status by telephone contact, mailed questionnaire, and
National Death Index search. We included only pa-
tients with ejection fraction at rest of 25%. We
excluded patients with significant valvular disease or
congenital heart disease. Follow-up was 95% com-
plete at 1 year and 87% complete at 2 years.
Patients underwent DSE according to a standard
protocol. The starting dose of dobutamine was 5 g/
kg/min. At 3-minute intervals, the dose was increased
according to protocol to 10, 20, 30, and 40 g/kg/min
with the optional addition of atropine (up to 1 mg).
The reasons for termination of the infusion before
receiving the maximum dose included attainment of
85% maximum predicted heart rate, severe angina,
significant arrhythmia, severe wall motion changes, or
systolic blood pressure 220 mm Hg. Standard
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Unrestricted Utilization of Sirolimus-Eluting Stents
Compared With Conventional Bare Stent Implantation in
the “Real World”
The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology
Hospital (RESEARCH) Registry
Pedro A. Lemos, MD; Patrick W. Serruys, MD, PhD; Ron T. van Domburg, PhD; Francesco Saia, MD;
Chourmouzios A. Arampatzis, MD; Angela Hoye, MBChB, MRCP; Muzaffer Degertekin, MD;
Kengo Tanabe, MD; Joost Daemen; Tommy K.K. Liu; Eugene McFadden, MBChB, FRCPI;
Georgios Sianos, MD, PhD; Sjoerd H. Hofma, MD; Pieter C. Smits, MD, PhD;
Willem J. van der Giessen, MD, PhD; Pim J. de Feyter, MD, PhD
Background—The effectiveness of sirolimus-eluting stents in unselected patients treated in the daily practice is currently
unknown.
Methods and Results—Sirolimus-eluting stent implantation has been used as the default strategy for all percutaneous
procedures in our hospital as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital
(RESEARCH) registry. Consecutive patients with de novo lesions (n508) treated exclusively with sirolimus-eluting
stents (SES group) were compared with 450 patients who received bare stents in the period just before (pre-SES group).
Patients in the SES group more frequently had multivessel disease, more type C lesions, received more stents, and had
more bifurcation stenting. At 1 year, the cumulative rate of major adverse cardiac events (death, myocardial infarction,
or target vessel revascularization) was 9.7% in the SES group and 14.8% in the pre-SES group (hazard ratio [HR], 0.62
[95% CI, 0.44 to 0.89]; P0.008). The 1-year risk of clinically driven target vessel revascularization in the SES group
and in the pre-SES group was 3.7% versus 10.9%, respectively (HR, 0.35 [95% CI, 0.21 to 0.57]; P0.001).
Conclusions—Unrestricted utilization of sirolimus-eluting stents in the “real world” is safe and effective in reducing both
repeat revascularization and major adverse cardiac events at 1 year compared with bare stent implantation. (Circulation.
2004;109:190-195.)
Key Words: stents  angioplasty  revascularization  restenosis
In-stent restenosis has long been recognized as the mainlimitation of coronary stenting, with rates of as high as
50% in more complex subsets. Recently, sirolimus-eluting
stent (SES) implantation has been proven to markedly reduce
the incidence of angiographic restenosis and repeat revascu-
larization in selected patients.1–3 In the First-In-Man study, no
cases of restenosis were detected in a series of 45 patients,
with persistent neointimal inhibition demonstrated up to 2
years.4 These findings have been further confirmed in ran-
domized trials comparing SES with conventional bare
stents.2,3 In the RAndomized study with the sirolimus-eluting
Bx VElocity balloon-expandable stent in the treatment
of patients with de novo native coronary artery Lesions
(RAVEL),2 there were no cases of binary angiographic
restenosis in patients treated with SES implantation. Simi-
larly, in the SIRolImUS-eluting Bx velocity balloon expand-
able stent trial (SIRIUS),3 restenosis occurred in 9% of cases
in the SES group compared with 36% of patients treated with
conventional stents (P0.001).
See p 140
Based on these findings, since the first half of 2002, SES
have progressively received clinical approval by official
regulatory agencies and are currently available for routine use
in Europe, Asia, South America, and more recently the
United States. However, all clinical trials completed so far
have included elective patients with relatively noncomplex
lesions. The effects of SES implantation in complex, un-
selected patients, such as those treated in daily practice,
remains largely unknown. Notably, the occurrence of reste-
nosis in a small but relevant proportion of patients in the
SIRIUS trial occurred mainly in patients with diabetes, small
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vessels, and long lesions,3 characteristics frequently found in
most series. Moreover, restenosis after SES implantation has
been recently shown to occur in association with procedures
with increased complexity.5 The present study was therefore
conducted to investigate the impact of SES on the outcomes
of patients treated in the “real world” of interventional
cardiology, as compared with a strategy using conventional
bare stent implantation.
Methods
Study Design and Patient Population
The study protocol of the Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital (RESEARCH) has been described
elsewhere.6 Briefly, the RESEARCH is a single-center registry
conducted with the main purpose of evaluating the safety and
efficacy of SES implantation for patients treated in daily practice. To
include a patient population representative of the “real world,” we
have adopted since April 16, 2002, a policy of using SES (Cypher;
Johnson & Johnson-Cordis unit, Cordis Europa NV) as the default
strategy for every percutaneous coronary intervention.
In the first 6 months enrollment, a total of 508 patients with de
novo lesions were treated exclusively with SES and were included in
the present report (SES group) (72% of the 710 patients treated with
stents in during the period). Patients treated with bare stents and SES
in the same procedure (66 patients) and those treated only with bare
stents (136 patients) were not included in the present report. At the
initiation of the RESEARCH registry, SES were available in lengths
of 8, 18, and 33mm and diameters from 2.25 to 3.00 mm, but
postdilation with larger balloons was allowed (0.5-mm larger bal-
loons were used in 55% of cases in which a 3.0-mm SES was used).
However, unavailability of an appropriate SES size was still the
reason for nonutilization of SES in 77% of cases. Moreover, 5% of
cases were included in the other study and were not enrolled in the
RESEARCH. In the remaining patients not included, SES were not
used for a variety of reasons, predominantly operator’s personal
choice.
Patients treated solely with SES were compared with a group of
consecutive patients treated with bare stents for de novo lesions in
the preceding 6 months (pre-SES group). To better match the vessel
sizes treated in the two study groups, patients receiving bare metal
stents larger than 3.5-mm were excluded from this analysis (n176).
This cutoff value (instead of 3.0-mm diameter stents) was chosen
because of the postdilation policy applied in the SES group, which
extended the use of SES to patients with 3.5-mm vessels by visual
estimation. In addition, patients treated with bare stents smaller than
2.25 mm were not included (n30). In total, 450 consecutive
patients thereby comprise the pre-SES group (69% of all patients
with de novo lesions treated with stents during the period). The
present study population was consequently composed of a total of
958 patients divided into two sequential cohorts, primarily distin-
guished by the interventional strategy applied (bare stent or SES
implantation, respectively). This protocol was approved by the
hospital ethics committee and is in accordance with the Declaration
of Helsinki. Written informed consent was obtained from every
patient.
Procedures and Postintervention Medications
All interventions were performed according to current standard
guidelines,7 and the final interventional strategy was entirely left to
the discretion of the operator. Angiographic success was defined as
residual stenosis 30% by visual analysis in the presence of TIMI 3
grade flow. Periprocedural glycoprotein IIbIIIa inhibitors and anti-
thrombotic medications were used according to the operator’s
decision. All patients were advised to maintain lifelong aspirin. At
least 1-month clopidogrel treatment (75 mg/d) was recommended for
patients treated in the pre-SES phase. For patients treated with SES,
clopidogrel was prescribed for at least 3 months, unless one of the
following was present (in which case clopidogrel was maintained for
at least 6 months): multiple SES implantation (3 stents), total
stented length 36 mm, chronic total occlusion, and bifurcations.
End Point Definitions and Clinical Follow-Up
The primary outcome was the occurrence of major adverse cardiac
events, defined as (1) death, (2) nonfatal myocardial infarction, or (3)
target vessel revascularization. Myocardial infarction was diagnosed
by a rise in the creatine kinase level to more than twice the upper
normal limit with an increased creatine kinase-MB. Target lesion
revascularization was defined as a repeat intervention (surgical or
percutaneous) to treat a luminal stenosis within the stent or in the
5-mm distal or proximal segments adjacent to the stent. Target vessel
revascularization was defined as a reintervention driven by any
lesion located in the same epicardial vessel. Thrombotic stent
occlusion was angiographically documented as a complete occlusion
(TIMI flow 0 or 1) or a flow-limiting thrombus (TIMI flow 1 or 2)
of a previously successfully treated artery.
Information about the in-hospital outcomes was obtained from an
electronic clinical database for patients maintained in our institution
and by review of the hospital records for those discharged to
referring hospitals (patients were referred from a total of 14 local
hospitals). Postdischarge survival status was obtained from the
Municipal Civil Registries. All repeat interventions (surgical and
percutaneous) and rehospitalizations were prospectively collected
during the follow-up. Questionnaires with information about anginal
status and medication usage were sent to all living patients. The
referring physicians and institutions were contacted whenever nec-
essary for additional information.
During follow-up, coronary angiography was obtained as clini-
cally indicated by symptoms or documentation of myocardial ische-
mia. Additionally, late angiographic evaluation was eventually
obtained from “complex” patients in the SES group, typically with
SES implanted in bifurcations, left main coronary, chronic total
occlusions, very small vessels, long stented length (36 mm), and
acute myocardial infarction (in total, 38% patients in the SES group
had angiographic follow-up between 6 and 8 months). No angio-
graphic re-study was performed in the pre-SES group. Because of the
well-known effect of angiographic reevaluation in increasing the
incidence of repeat revascularization,8 all reinterventions were ret-
rospectively adjudicated and classified as clinically driven or non-
clinically driven by a group of clinicians not involved in the
treatment of the particular patient analyzed. Clinically driven repeat
revascularization was defined as any intervention motivated by a
significant luminal stenosis (50% diameter stenosis) in the pres-
ence of anginal symptoms and/or proven myocardial ischemia in the
target vessel territory by noninvasive testing.
Statistical Analysis
Continuous variables were presented as meanSD and were com-
pared by means of the Student unpaired t test. Categorical variables
were presented as counts and percentages and compared by means of
the Fisher exact test. All statistical tests were 2-tailed. The cumula-
tive incidence of adverse events was estimated according to the
Kaplan-Meier method, and Cox proportional hazards models were
used to assess risk reduction of adverse events. Patients lost to
follow-up were considered at risk until the date of last contact, at
which point they were censored. Multivariate analyses were per-
formed to identify independent predictors of adverse events, using all
clinical, angiographic, and procedural variables included in Tables 1
and 2.
Results
Baseline and Procedural Characteristics
Baseline and procedural characteristics are shown in Table 1
and Table 2. Overall, approximately half of the patients in
both groups were admitted with acute coronary syndromes,
and diabetes was present in 16% of cases. Patients treated
with SES had significantly more multivessel disease, more
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type C lesions, more bifurcation stenting, more segments
stented, and more stents used. Also, in the SES group, long
stents and stents with smaller diameters were more frequently
used. Periprocedural administration of glycoprotein IIbIIIa
inhibitors was more frequent in the pre-SES phase (33%
versus 19%; P0.01). The angiographic success rate was
similar in both groups.
Clinical Outcomes
Complete follow-up information was available for 99.1% of
patients (mean follow-up period, 405 days). There were no
significant differences between the SES group and the pre-
SES group in the incidence of major adverse cardiac events
during the first month (3.0% versus 4.2% respectively;
P0.3) (Table 3). Target vessel revascularization at 30 days
was 1.0% (n5) in the SES group and 2.2% (n10) in the
pre-SES group (P0.2), which included emergency bypass
surgery in 2 patients (0.4%) in the SES group and in 2 cases
(0.4%) in the pre-SES group (P1.0) and early “redo” target
vessel revascularization (eg, residual dissection or compro-
mised side branch in patients with continuing symptoms) in 1
patient (0.2%) in the SES group and in 1 patient (0.2%) in the
pre-SES group (P1.0). In the remaining cases, 30-day
repeat intervention was performed for angiographically doc-
umented stent thrombosis in 2 patients (0.4%) in the SES
group and in 7 patients (1.6%) in the pre-SES group (P0.1).
No further thrombotic stent occlusion was observed in the
late follow-up.
At 1 year, the cumulative incidence of death and death or
myocardial infarction was similar between both groups (Fig-
ure 1, A and B). Patients treated with SES had significantly
less death, myocardial infarction, or target lesion revascular-
ization at 1 year than patients treated in the pre-SES phase
(8.8% versus 12.6%, respectively; hazard ratio [HR] 0.66
TABLE 1. Baseline Characteristics of Patients Treated With
Conventional Bare Stents Before Introduction of SES (Pre-SES
Group) and Patients Treated Exclusively With SES Implantation
(SES Group)
Pre-SES
Group
(n450)
SES
Group
(n508) P
Male, % 72 68 0.4
Age, ySD 6111 6111 0.7
Diabetes, % 15 18 0.3
Non–insulin-dependent, % 11 12 0.7
Insulin-dependent, % 4 6 0.2
Hypertension, % 48 41 0.2
Hypercholesterolemia, % 55 56 1.0
Current smoking, % 34 31 0.3
Previous myocardial infarction, % 40 30 0.01
Previous angioplasty, % 18 19 0.8
Previous coronary bypass surgery, % 8 9 0.5
Single-vessel disease, % 52 46 0.05
Multivessel disease, % 48 54 0.05
Clinical presentation       0.7
Stable angina, % 48 45   
Unstable angina, % 35 37   
Acute myocardial infarction, % 18 18   
Cardiogenic shock, %* 12 10 0.7
*Relative to patients with acute myocardial infarction.
TABLE 2. Angiographic and Procedural Characteristics of
Patients Treated With Conventional Bare Stents Before
Introduction of SES (Pre-SES Group) and Patients Treated
Exclusively With SES Implantation (SES Group)
Pre-SES
Group
(n450)
SES
Group
(n508) P
Treated vessel
Left anterior descending, % 59 59 0.8
Left circumflex, % 33 32 0.7
Right coronary artery, % 34 39 0.2
Left main coronary, % 2 3 0.6
Bypass graft, % 2 3 0.2
Lesion type
Type A, % 20 22 0.4
Type B1, % 32 31 0.7
Type B2, % 50 49 0.8
Type C, % 30 43 0.01
Glycoprotein IIbIIIa inhibitor, % 33 19 0.01
Clopidogrel prescription,
monthsSD
2.92.0 4.02.0 0.01
Bifurcation stenting, % 8 16 0.01
No. of stented segmentsSD 1.80.9 2.01.0 0.01
No. of implanted stentsSD 1.91.2 2.11.4 0.01
Individual stent length 33 mm, % 10 35 0.01
Total stented length per
patient, mmSD
30.119.6 38.728.7 0.01
Nominal stent diameter
2.5 mm, %
23 36 0.01
Postdilation with a balloon
0.5 mm larger, %
19 55 0.01
Angiographic success of all
lesions, %
97 97 1.0
TABLE 3. Thirty-Day Outcomes of Patients Treated With
Conventional Bare Stents Before Introduction of SES (Pre-SES
Group) and Patients Treated Exclusively With SES Implantation
(SES Group)
Pre-SES
Group
(n450)
SES
Group
(n508) P *
Death, % 2.0 1.6 0.6
Nonfatal myocardial infarction, % 1.6 0.8 0.4
Target lesion revascularization, % 1.8 1.0 0.4
Target vessel revascularization, %† 2.2 1.0 0.2
Any event, % 4.2 3.0 0.3
Stent thrombosis, %‡ 1.6 0.4 0.1
*By Fisher exact test.
†Includes target lesion revascularization.
‡Angiographically documented stent thrombosis requiring repeat intervention.
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[95% CI, 0.45 to 0.97]; P0.03) (Figure 1C). Similarly, the
1-year cumulative risk of major adverse cardiac events
(death, myocardial infarction, or target vessel revasculariza-
tion) was significantly reduced in the SES group (9.7% versus
14.8% in the pre-SES group; HR, 0.62 [95% CI, 0.44 to
0.89]; P0.008). The difference in outcomes between both
groups was mainly due to a decrease in the need for target
vessel revascularization in the SES group (5.1% versus
10.9% in the pre-SES group; HR, 0.49 [95% CI, 0.29 to
0.82]; P0.007). Specifically, treatment with SES was asso-
ciated with a marked reduction in clinically driven repeat
interventions at 1 year (3.7% versus 10.9% in the pre-SES
group; HR, 0.35 [95% CI, 0.21 to 0.57]; P0.001) (Figure 2).
Predictors of Adverse Events
The impact of SES implantation on the risk of subsequent
clinically driven target vessel revascularization in specific
subsets is shown in Figure 3. SES implantation was associ-
ated with a risk reduction that ranged from 28% to 79%
across the subgroups evaluated. However, the benefit of SES
did not reach statistical significance in women (HR, 0.59
[95% CI, 0.24 to 1.45]; P0.25) and diabetics (HR, 0.72
[95% CI, 0.30 to 1.77]; P0.50). Patients treated with
bifurcation stenting (HR, 0.38 [95% CI, 0.13 to 1.13];
P0.08) and patients receiving 33-mm or longer stents (HR,
0.41 [95% CI, 0.16 to 1.03]; P0.06) presented a strong trend
to have better outcomes with SES implantation. In the other
subgroups, SES use significantly decreased the need of repeat
intervention (Figure 3). Importantly, the postdilation strategy
applied in the present study did not influence the clinical
benefit of SES implantation. The magnitude of the risk
reduction was similar between patients treated with postdila-
tion (HR, 0.28 [95% CI, 0.13 to 0.62]; P0.002) or without
postdilation (HR, 0.35 [95% CI, 0.18 to 0.70]; P0.003)
procedures.
Multivariate Cox proportional hazards analysis identified
SES utilization to be independently associated with a reduced
risk of adverse clinical events (Table 4). After adjustment for
other independent variables, SES significantly decreased the
Figure 1. One-year adverse events in patients treated with bare
stents before the introduction of SES (pre-SES group) and in
patients treated exclusively with SES implantation (SES group). A,
Cumulative risk of death; B, death or myocardial infarction; C,
death, myocardial infarction, or target lesion revascularization; and
D, death, myocardial infarction, or target vessel revascularization.
Figure 2. One-year cumulative risk of clinically driven target
vessel revascularization in patients treated with bare stents
before introduction of SES (pre-SES group) and in patients
treated exclusively with SES implantation (SES group).
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risk of clinically driven target vessel revascularization (ad-
justed HR, 0.33 [95% CI, 0.20 to 0.56]; P0.01) and the risk
of major adverse cardiac events (adjusted HR, 0.55 [95% CI,
0.38 to 0.80]; P0.01).
Discussion
SES implantation has been shown to markedly decrease the
incidence of in-stent restenosis in the context of randomized
trials.2,3 However, these studies have enrolled relatively
noncomplex patient populations referred for elective inter-
vention. As a consequence, the findings from these studies
cannot be directly extrapolated to many patients treated in the
everyday practice, where complex, nonelective cases are the
rule rather than the exception. In the present study, SES
implantation was associated with a reduction in the rates of
repeat revascularization and major adverse cardiac events at 1
year in a consecutive, unselected cohort of patients. SES
implantation resulted in a relative reduction of 51% in the
overall rate of target vessel revascularization and of 65% in
the rate of clinically driven target vessel revascularization.
Our series compared a strategy of unrestricted usage of
SES with conventional approaches that used bare stents in the
pre-SES era. Although the two study groups were consecu-
tively included over a total period of only 1 year, some
important differences were noted in the interventional strat-
egy applied. Patients in the SES phase were treated with a less
restrictive interventional approach, with a significant increase
in the number and length of stents implanted, number of
coronary segments dilated, bifurcation stenting, and decrease
in the diameter of the stents. Possibly, this change in practice
may reflect the early recognition by the operators that the
acute results, even in this complex population, were main-
tained in the medium term. Also, it may reflect an attempt to
accomplish more complete lesion coverage and ensure uni-
form drug delivery over the entire diseased segment, since
stent discontinuity and edge injury have been recently shown
by our group to be associated with post-SES restenosis.5
Moreover, the higher complex profile of patients treated with
SES (eg, high rates of multivessel disease, type C lesions,
bifurcations) may translate a change in the decision-making
process promoted by the availability of SES in our institution.
Although both study groups differed in some baseline and
procedural characteristics, which may somewhat limit an
unbiased comparison between them, it is worth noting that
most if not all differences would be traditionally expected to
increase the incidence of late complications in the SES-
treated patients. Nevertheless, the treatment effect of SES
was significantly higher than bare stents, remaining virtually
unaffected after adjustment for procedural characteristics.
The reduction of adverse events after SES implantation in
our series is lower than that observed in the RAVEL trial, in
which no binary angiographic restenosis was diagnosed.2 The
present findings more closely resemble those seen in the
SIRIUS trial (75% reduction in clinically driven target lesion
Figure 3. Hazard ratio of 1-year clinically
driven target vessel revascularization
(Cox proportional hazards models) in
subgroups of patients according to
baseline and procedural characteristics.
TABLE 4. Multivariate Predictors of Adverse Events (Cox
Proportional Hazards Model)
HR 95% CI P
Major adverse cardiac events*
SES utilization 0.55 0.38–0.80 0.01
Cardiogenic shock 4.73 2.31–9.70 0.01
Diabetes mellitus 1.62 1.09–2.43 0.02
Left main stenting 2.93 1.48–5.82 0.01
Utilization of at least one 33-mm-long stent 1.54 1.02–2.33 0.04
Clinically driven target vessel revascularization
SES utilization 0.33 0.20–0.56 0.01
Acute coronary syndromes† 0.51 0.32–0.80 0.01
No. of stented segments 1.25 1.01–1.55 0.04
Diabetes mellitus 1.81 1.10–2.99 0.02
*Major adverse cardiac events: death, myocardial infarction, or target
vessel revascularization.
†Unstable angina or acute myocardial infarction at admission.
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revascularization), in which patients with higher risk profiles
were included.3 Compared with the RAVEL study, the relative
decline in effectiveness in the SIRIUS trial and in the RE-
SEARCH study may have been related to the complexity of the
procedures included. Although SES implantation markedly re-
duced the risk of subsequent revascularization in most subsets,
the benefit of the new treatment did not reach statistical signif-
icance in some subgroups in our series. Indeed, the presence of
diabetes and treatment of long lesions were shown to indepen-
dently increase the incidence of complications. These findings
highlight the need of further analyses with larger numbers of
patients to fully estimate the clinical impact of SES in these
patients. Also, whether the outcomes of higher-risk subgroups
can be improved with refinements in the procedural techniques
remains to be established.
Importantly, the reduction of late complications was accom-
plished without any increase in unexpected sudden events. Our
results extend the findings observed in an early report6 and show
that SES implantation in complex patients is safe, with no
increase in acute device-related adverse events. The incidence
(0.4%) and timing (within the first month) of documented
thrombotic stent occlusion in the SES group was compatible
with the current results with conventional bare metal stents. The
utilization of IIbIIIa inhibitors and clopidogrel differed between
both study groups. However, these differences did not signifi-
cantly influence the clinical outcome in our study. Nevertheless,
it should be noted that these agents were not uniformly used
across the various patient subsets, being mainly used in cases at
a higher risk of complications, which may have blunted the
overall positive effect of these drugs.
Although restenotic lesions have been shown to be ame-
nable to treatment by SES,9,10 the treatment of de novo
lesions may be considered as the main field of application of
the new device. In this regard, this study was conducted to
evaluate the use of SES as a prophylactic strategy in prevent-
ing rather than treating in-stent restenosis in the “real world.”
Some patients were not treated with the SES during the
time period of the study. However, in most instances, this was
due to unavailability of large-diameter SES. As large vessels
have been shown to present a lower risk of restenosis,3 it is
quite possible that the noninclusion of patients with larger
vessels may have resulted in an underestimation of the overall
treatment effect in the present report. The present study is a
single-center experience from a tertiary referral center and
lacks the obvious advantages of a multicenter, multinational
randomized study. Furthermore, it is unlikely that a random-
ized study will be conducted in the context in which this
study was performed, with virtually no exclusion criteria.
Conclusions
This study demonstrates that unrestricted utilization of SES in
the “real world” is safe and effective in reducing the need of
further revascularization and the incidence of major adverse
cardiac events after 1 year, as compared with patients treated
with bare stent implantation in the period immediately before.
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Clinical and Angiographic Outcomes After Overdilatation
of Undersized Sirolimus-Eluting Stents With Largely
Oversized Balloons: An Observational Study
Francesco Saia, MD, Pedro A. Lemos, MD, Chourmouzios A. Arampatzis, MD, Angela Hoye,
Eugene McFadden, Georgios Sianos, MD, Pieter C. Smits, MD, PhD,
Willem J. van der Giessen, MD, PhD, Pim J. de Feyter, MD, PhD, Ron T. van Domburg, PhD, and
Patrick W. Serruys,* MD, PhD
The purpose of this study was to assess the safety and effectiveness of sirolimus-eluting
stent (SES) postdilatation with largely oversized balloons. We evaluated the clinical
outcome of 68 consecutive patients enrolled in the Rapamycin-Eluting Stent Evaluated at
Rotterdam Cardiology Hospital (RESEARCH) registry who underwent percutaneous cor-
onary intervention with SES implantation and further postdilatation with balloons> 1 mm
larger than the stent nominal size. Angiographic follow-up was either scheduled for
selected subgroups or clinically driven. Overall, 75 lesions were treated. The procedure
was successful in 98.5% of the cases. One patient (1.5%) underwent emergency coronary
bypass surgery for acute vessel occlusion. During 10.1  1.7 months of follow-up, three
patients (4.5%) died, one (1.5%) had acute myocardial infarction, and four (6%) had target
vessel revascularization. At angiographic follow-up, loss index was 0.13  0.34 and
restenosis rate was 7.7%. Although not routinely recommended in every patient, SES
postdilatation with largely oversized balloons appears a safe and effective strategy for
selected patients. Catheter Cardiovasc Interv 2004;61:455–460. © 2004 Wiley-Liss, Inc.
Key words: angioplasty; stent; sirolimus
INTRODUCTION
Stent-based local drug delivery is a relatively new
concept developed to prevent neointima hyperplasia
growth and restenosis following coronary angioplasty
and stenting [1]. While the stent, with its mechanical
properties, prevents elastic recoil and negative vessel
remodeling, the drug bound on its surface exerts an
inhibitory action toward smooth muscle cell proliferation
and migration, the most important determinants of in-
stent restenosis (ISR).
Sirolimus-eluting stents (SESs) have been shown in
randomized trials to virtually abolish in-stent restenosis
in selected patients with de novo lesions [2]. The revo-
lutionary results obtained in the first studies have encour-
aged, in a few pioneer centers, the routine utilization of
these new devices, with the double aim of giving the best
treatment available to all patients and, at the same time,
assessing the efficacy of SESs in more complex clinical
subsets of patients and lesions, such as those found in the
daily practice [3].
Several intravascular ultrasound (IVUS) studies have
shown that optimal stent deployment was rarely achieved
with angiographically guided angioplasty alone [4–6].
The major effect of these studies was the introduction of
routine high-pressure stenting [5,7]. Moreover, stent
postdilatation with larger balloons has become common
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practice after the documentation of the frequent mis-
match between the angiographic and the real vessel di-
ameter [8–10], and the very low incidence of in-stent
restenosis observed in the MUSIC study with IVUS-
guided stent deployment [11]. The choice to postdilate a
stent depends on many factors: operator’s habit, attempt
to improve suboptimal angiographic results, IVUS-
guided stenting. In the AVID study, which evaluated the
effects of IVUS-guided stent, additional balloon dilata-
tion based on IVUS findings was performed in 43% of
the patients [12]. Similarly, in the CRUISE study, after
IVUS examination, the operators decided to use over-
sized balloons in 34% of the patients [13]. This strategy
has been proven to be safe with bare stents and was not
reported to hamper the efficacy of drug-eluting stents in
the RAVEL trial [2], where it was allowed in order to
achieve a less than 20% residual in-stent diameter steno-
sis.
In daily practice, based on angiographic or intravas-
cular ultrasound findings, extreme overdilatation with
balloon  1 mm larger than the stent nominal size might
be required in selected cases to achieve a good proce-
dural result. Moreover, temporary limited availability of
properly sized stents could be related to local laborato-
ry’s or manufacturers’ problems. In the SES, sirolimus is
blended in a 5 m thick layer of nonerodable polymer.
Appropriate drug delivery depends on the polymer integ-
rity and on the proper spatial distribution of the stent
struts. Extreme postdilatation of the stent could impair
the effectiveness of SES in different ways: by enhancing
tissue proliferation in response to greater vessel injury
[14], by altering the mechanical properties of the stent,
by disrupting the polymer coating, and by increasing the
distance between the stent struts, therefore reducing local
drug distribution.
In the present study, we evaluated the clinical and
angiographic outcomes of 68 patients treated with SES
implantation in which a postdilatation with largely over-
sized balloons was performed.
MATERIALS AND METHODS
Patient Population
SES implantation was adopted as the default strategy
for all patients undergoing PCI at our institution as part
of the Rapamycin-Eluting Stents Evaluated at Rotterdam
Cardiology Hospital (RESEARCH) registry [3]. The SES
was available in limited lengths (8, 18, and 33 mm) and
diameters (2.25, 2.5, 2.75, and 3.0 mm). In a 4-month
period from June to October 2002, 68 consecutive pa-
tients underwent SES implantation and further postdila-
tation with balloons  1 mm larger than the stent nom-
inal size and comprise the present study population.
Procedure
All procedures were performed according to standard
techniques, and the final interventional strategy, as well
as periprocedural adjunctive medications and intravascu-
lar ultrasound utilization, was left to the operator’s dis-
cretion. All patients were pretreated with aspirin and
clopidogrel. Aspirin was maintained lifelong and at least
3 months of clopidogrel treatment was recommended
thereafter. Prolonged clopidogrel prescription (6 months)
was recommended for patients treated with SES and at
least one of the following characteristics: multiple SES
( 3 stents), total stented length  36 mm, chronic total
occlusion, bifurcations, and in-stent restenosis. The study
protocol was approved by the institutional ethics com-
mittee and written informed consent was obtained from
all patients.
Definitions and Follow-Up
A procedure was considered successful when residual
stenosis was  30% by quantitative coronary analysis
together with TIMI flow 3. During follow-up, coronary
angiograms were obtained as clinically indicated by
symptoms or positive ischemic tests. In addition, fol-
low-up angiograms were scheduled for patients with SES
implantation to treat in-stent restenosis, bifurcations, left
main, chronic total occlusions, very small vessels (SES
diameter 2.25 mm), long stent length ( 36 mm), and
acute myocardial infarction. Post-SES binary restenosis
at follow-up was defined as  50% diameter stenosis
occurring in the segment inside the SES or within 5 mm
segment proximal or distal to the stent. Acute gain was
defined as the difference between minimal luminal diam-
eter (MLD) post- and preprocedure. Late loss was cal-
culated as the difference between the MLD immediately
after the procedure and the MLD at 6 months. Loss index
was defined as the ratio between late loss and acute gain.
The incidence of major adverse cardiovascular events
(MACEs), defined as death, myocardial infarction, or
target vessel revascularization (TVR), was evaluated. A
definite diagnosis of MI required an increase in the
creatine kinase level to more than twice the upper normal
limit with an increased level of creatine kinase-MB.
Target lesion revascularization (TLR) was defined as
any surgical or percutaneous reintervention motivated by
a significant luminal narrowing within the stent or in the
5 mm distal or proximal peristent segments. TVR was
defined as any reintervention driven by lesions located in
the treated vessel even beyond the target lesion limits.
Statistical Analysis
Discrete variables are reported as counts and relative
percentages. Continuous variables are expressed as
mean  standard deviation.
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RESULTS
Baseline and Procedural Data
Baseline clinical characteristics of the 68 patients are
shown in Table I. Around 15% of the patients had dia-
betes mellitus and 56% multivessel coronary disease.
Notably, 23.5% of the patients presented acute myocar-
dial infarction. Overall, 75 lesions were treated with 101
sirolimus-eluting stents, with an average stent length per
lesion of 26.9  18.0 mm. Among the lesions, seven
(9.3%) were in the left main and nine (12%) in a saphe-
nous vein graft. Chronic total occlusions ( 3 months)
accounted for 24% of the procedures. Nominal stent
diameter was 3.0 mm in 98 cases, 2.75 mm in 2, and 2.5
in 1. Further stent postdilatation was performed with a
4.0 mm balloon in 70 lesions and with 4.5 mm balloon in
the remaining 5. Average inflation pressure was 15.9 
3.6 atm. Nominal balloon-to-artery ratio was 1.31 
0.29. IVUS was used in 21 patients (30.8%). In 85.3% of
the cases, the SES was implanted to treat a de novo
lesion, in 9.3% to treat in-stent restenosis, and in 4% to
treat a guiding catheter-induced vessel dissection (Table
II). Glycoprotein IIb/IIIa inhibitors were used in 38.2%
of the patients. The procedure was successful in 67
patients (98.5%). One patient developed diffuse distal
vessel dissection after postdilatation of the 3  18 mm
SES with a 4  15 mm balloon, inflated up to 12 atm,
and underwent successful emergency CABG.
Clinical Follow-Up
Clinical follow-up was available for 67 patients
(98.5%). During an average follow-up of 10.1  1.7
months, three (4.5%) patients died, one (1.5%) had acute
myocardial infarction, and four (6%) had a TVR, of
which three were TLR (4.5%). Overall MACE rate was
12.0%. One patient was admitted with acute large infero-
posterior myocardial infarction and cardiogenic shock,
which was irreversible despite positioning of intra-aortic
balloon pump. A second patient died 5 months after the
procedure because of end-stage renal failure. The cause
of death of the third patient, who died 141 days after the
revascularization procedure, is unknown: he was 75
years old, diabetic, with three-vessel disease and moder-
ate aortic valve stenosis, and had received an SES in the
proximal right coronary artery. One patient had a small
periprocedural myocardial infarction (CK max  346
UI/L; MB 73 UI/L). The angioplasty was performed in
a saphenous vein graft, which was totally occluded due to
in-stent restenosis. Among the four target vessel reinter-
ventions, only one was motivated by restenosis. The
remaining were one case of emergency bypass surgery,
already described, one early (5 days) percutaneous rein-
tervention caused by incomplete ostial coverage of the
right coronary artery during the index procedure, and one
case of in-stent redilatation driven by IVUS diagnosis of
stent undersizing despite the absence of angiographic
restenosis (the patient was symptomatic and presented
angiographic restenosis in another lesion located distally
in the same vessel, a saphenous vein graft). There were no
documented episodes of early or late stent thromboses.
Angiographic Results
Angiographic follow-up was obtained in 34 patients
for 39 lesions after 210  29 days (range, 156–309
TABLE I. Baseline Patient Characteristics
Patients, n 68
Age, years 60  10
Male 45 (66.2%)
Risk factors
Current smoker 24 (35.3%)
Hypercholesterolemiaa 40 (58.8%)
Systemic hypertension 22 (32.4%)
Diabetes mellitus 10 (14.7%)
Family history of coronary heart disease 32 (47.1%)
Clinical presentation
Silent ischemia 3 (4.4%)
Stable angina pectoris 30 (44.1%)
Unstable angina pectoris 19 (27.9%)
Acute myocardial infarction 16 (23.5%)
Multivessel coronary disease 38 (55.9%)
Previous myocardial infarction 21 (30.1%)
Previous coronary bypass 9 (13.2%)
Previous percutaneous coronary intervention 17 (25%)
aTotal cholesterol  200 mg/dl and/or on lipid-lowering treatment.
TABLE II. Angiographic and Procedural Characteristics
Lesions, n 75
Target coronary artery
Left anterior descending 21 (28.0%)
Left circumflex artery 6 (8.0%)
Right coronary artery 32 (42.7%)
Left main 7 (9.3%)
Saphenous vein graft 9 (12.0%)
Lesion type
De novo 64 (85.3%)
In-stent restenosis 7 (9.3%)
Early reintervention 1 (1.3%)
Guiding catheter injury/dissection 3 (4.0%)
Lesion type (AHA/ACC classification)
Type A 4 (5.3%)
Type B1 18 (24.0%)
Type B2 29 (38.7%)
Type C 24 (32.0%)
Thrombus-containing lesions 16 (21.3%)
Moderate/severe calcifications 9 (12.0%)
Ostial lesions 23 (30.7%)
Bifurcation stenting 4 (5.2%)
Chronic total occlusions 18 (24%)
Glycoprotein IIb/IIIa inhibitorsa 26 (38.2%)
Stent per lesion, n 1.35  0.65
Stents length per lesion, mm 26.9  18.0
aPercentage relative to the number of patients (68).
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days). As previously specified, the reasons for repeat
catheterization were elective follow-up because the pa-
tient was included in selected subgroups in 32 cases
(72.7% of the 44 patients scheduled for 6-month angiog-
raphy) and clinically driven recatheterization in 2 pa-
tients. At baseline, mean reference diameter was 3.21 
0.58 mm, MLD 0.86  0.61 mm, percent diameter
stenosis 72% 21%, and lesion length 17.9 11.5 mm.
Paired quantitative coronary analysis for patients with
angiographic follow-up is shown in Table III. Late loss
was 0.24  0.61 mm, with 76% of the cases in the range
between 0.5 and 0.5 mm. Loss index was 0.13  0.34.
Overall, post-SES binary restenosis was observed in
three lesions (7.7%): two were proximal edge restenosis,
and in one patient the vessel was occluded approximately
30 mm proximally to the target lesion.
DISCUSSION
In the present study, we show that postdilatation of
sirolimus-eluting stents with largely oversized balloons
is relatively safe and associated with good angiographic
results.
IVUS studies have demonstrated that incomplete stent
deployment may occur in a considerable number of pa-
tients even with high-pressure techniques [6,15]. Optimal
stent expansion plays a key role in the prevention of stent
thrombosis [4]. Moreover, previous studies have shown
that residual percent diameter stenosis after stent implan-
tation is directly related to the development of restenosis
[16,17]. Similarly, in-stent minimal lumen cross-sec-
tional area measured by IVUS is inversely related to
restenosis [18]. All together, these findings provide the
rationale to pursue optimal stent expansion. This out-
come is often achieved by performing stent postdilatation
with balloons oversized with respect to the nominal stent
size. Overdilatation with balloons  0.25 mm larger has
been shown to improve lumen gain and possibly reduce
the need for target vessel revascularization, without in-
creasing complications [9,10,19]. However, in one study,
IVUS examination revealed that even with this strategy,
no stent reached its nominal size [19]. Thus, it is com-
monly believed that postdilatation with balloons up to 0.5
mm larger than the stent nominal size can be safely
accomplished in most of the cases. Conversely, dilatation
with balloons  0.5 mm larger than the stent nominal
size is a rare procedure. In clinical practice, this extreme
postdilatation is performed in selected patients, com-
monly when the operator has the perception, based on
angiographic or IVUS findings, that the stent implanted
is markedly undersized relatively to the vessel diameter.
In other situations, this choice could be driven, in a
bailout procedure, by unavailability of the proper size of
stents. In both cases, this strategy should be regarded as
an extreme solution, not free from potential complica-
tions. Possible stent structure distortion and disruption
must be taken into account, as well as the chance of
extensive intimal dissection and vessel wall rupture.
When the same strategy is applied with drug-eluting
stents, further possible shortcomings should be consid-
ered. In fact, the success of drug-eluting stents depends
critically on the achievement of the appropriate local
drug concentration, which warrants potent antiprolifera-
tive effects and preserved vascular healing. The elution
profile and release kinetics of the drug depend on the
biological properties of the drug and of the coating ma-
trix [1]. Apart from the potential mechanical damages to
the stent, excessive SES postdilatation could impair their
antiproliferative properties by damaging the polymer
coating. Moreover, by increasing the distance between
the drug-carrying stent struts, overdilatation could de-
crease local sirolimus concentration to a suboptimal or
ineffective level. The results of the present study suggest
that these potential risks do not have an evident impact
on the favorable clinical and angiographic outcome of
SES, although some negative influence cannot be ruled
out in single cases [20]. In our series, extreme SES
postdilatation was not associated with a high rate of acute
complication, although one patient had to be referred for
emergency coronary surgery. The clinical outcome at
mid-term follow-up was favorable, and the 12% inci-
dence of MACEs appears very satisfactory if we consider
TABLE III. Paired Quantitative Angiographic Analysis at Baseline, Postprocedure,
and Follow-Up for Patients With Angiographic Follow-Up
Preprocedure Postprocedure Follow-up
Reference diameter, mm 3.18  0.63 3.36  0.40 3.43  0.46
Minimum lumen diameter, mm 0.68 0.62 2.88  0.42 2.66  0.77
Diameter stenosis, % 77  22 14  9 20  21
Lesion length, mm 20.1  14.1
Acute gain, mm 2.22  0.73
Late loss,a mm 0.24  0.61
Loss index 0.13  0.34
Binary post-SES restenosis, % 7.7%
aIncluding one total reocclusion.
458 Saia et al.
Clinical and Angiographic Outcomes After Over-Dilatation of Undersized Sirolimus-Eluting Stents
73
the unselected nature of the population analyzed, which
included 24% of the patients with acute myocardial in-
farction. Notably, 9% of the lesions treated were in the
left main and 12% in a saphenous vein graft. Moreover,
at angiographic follow-up, restenosis was observed in a
very limited number of patients. Although only 50% of
the patients underwent repeat catheterization, the selec-
tion criteria of these patients (complex lesions and symp-
tomatic patients) would have been expected to increase
the chance of finding restenotic lesions, thus indirectly
confirming the very positive results obtained. Remark-
ably, almost one-fourth of the lesions were chronic total
occlusions, condition traditionally associated with higher
restenosis rates [21,22]. Indeed, the loss index of the
present series (0.13  0.34) compares favorably with the
historical series of the BENESTENT trial (0.46  1.39),
the BENESTENT II Pilot study (0.41  1.18), and the
MUSIC study (0.45  0.33) using bare stents (Table IV)
[11].
In conclusion, angiographically or intravascular-
guided postdilatation of SES with largely oversized bal-
loons could be considered an extreme solution for stent
undersizing. Although careful case-by-case evaluation in
these situations is necessary, this strategy appears rela-
tively safe and does not seem to impair the effectiveness
of sirolimus-eluting stents.
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Coronary Restenosis After Sirolimus-Eluting
Stent Implantation
Morphological Description and Mechanistic Analysis From a Consecutive
Series of Cases
Pedro A. Lemos, MD; Francesco Saia, MD; Jurgen M.R. Ligthart, BSc;
Chourmouzios A. Arampatzis, MD; Georgios Sianos, MD; Kengo Tanabe, MD;
Angela Hoye, MBChB, MRCP; Muzaffer Degertekin, MD; Joost Daemen; Eugene McFadden, MB;
Sjoerd Hofma, MD; Pieter C. Smits, MD, PhD; Pim de Feyter, MD, PhD;
Willem J. van der Giessen, MD, PhD; Ron T. van Domburg, PhD; Patrick W. Serruys, MD, PhD
Background —We describe the clinical and morphological patterns of restenosis after sirolimus-eluting stent (SES)
implantation.
Methods and Results—From 121 patients with coronary angiography obtained 30 days after SES implantation,
restenosis (diameter stenosis50%) was identified in 19 patients and 20 lesions (located at the proximal 5-mm segment
in 30% or within the stent in 70%). Residual dissection after the procedure or balloon trauma outside the stent was
identified in 83% of the proximal edge lesions. Lesions within the stent were focal, and stent discontinuity was identified
in some lesions evaluated by intravascular ultrasound.
Conclusions—Sirolimus-eluting stent edge restenosis is frequently associated with local trauma outside the stent. In-stent
restenosis occurs as a localized lesion, commonly associated with a discontinuity in stent coverage. Local conditions
instead of intrinsic drug-resistance to sirolimus are likely to play a major role in post-SES restenosis. (Circulation. 2003;
108:257-260.)
Key Words: restenosis  stents  angioplasty
Sirolimus-eluting stents (SES) have been reported to re-duce restenosis by inhibiting neointimal growth,1 though
post-SES restenosis may still occur in some cases.2 Currently,
the clinical and morphological features of restenosis after
SES implantation are unknown. In this study, we describe a
consecutive series of patients with angiographic restenosis
after SES implantation.
See p 248
Methods
Since April 2002, SES (Cypher; Cordis Europa NV) have been used
as the device of choice for percutaneous coronary intervention in our
institution, as part of the Rapamycin-Eluting Stent Evaluated At
Rotterdam Cardiology Hospital (RESEARCH) registry,3 a single-
center registry designed to evaluate the impact of SES implantation
in the “ realworld.” During follow-up, coronary angiograms were
obtained as clinically indicated by symptoms or positive ischemic
tests. In addition, follow-up angiograms were obtained at 61 month
for “ complex”patients, typically with SES implantation to treat
in-stent restenosis, bifurcations, left main, chronic total occlusions,
very small vessels (SES diameter 2.25 mm), long stented length
(36 mm), and acute myocardial infarction. Intravascular ultrasound
(IVUS) was performed at the discretion of the operator. The study
protocol was approved by the institutional ethics committee, and
written informed consent was obtained from all patients.
Binary restenosis was defined by diameter stenosis 50% and
classified as (1) in-stent, if inside the stent, or (2) edge restenosis, if
located within the 5-mm segments distal or proximal to the stent
margins. Restenosis at an ostial location was classified as in-stent,
unless clearly located outside the limits of the SES, in which case it
was classified as edge restenosis. Discrete variables were presented
as counts and percentages. Continuous variables were presented as
meanSD and compared by Student’s t test.
Results
To date, 192 patients with at least one of the aforementioned
“ complex”characteristics have completed 7 months from
the index procedure. A coronary angiogram performed 30
days after the angioplasty was obtained in 121 patients (221
lesions). Among these, post-SES restenosis was identified in
19 patients and 20 lesions (Table). IVUS was available at
follow-up for 11 patients with restenosis (58%). In total, 6
lesions (30%) were located at the proximal edge and 14 were
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in-stent (70%). Local injury outside the stent was observed in
5 cases of edge restenosis (83%), as evidenced by the
presence of angiographic or IVUS residual dissection after
the procedure (patients 1, 3, and 4), by balloon dilation at a
nonstented area in a patient with extensive manipulation
before and after implantation of 4 stents for acute occlusion
(patient 2), or by balloon postdilation outside the stent
(patient 5).
Patients With Restenosis After Sirolimus-Eluting Stent Implantation: Clinical, Procedural, and Morphological Characteristics
Patient No. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Total
Age, y 63 77 52 66 70 78 77 58 69 43 58 50 52 50 46 72 45 48 61 56
11
Gender M M M M M F M M F M M M M M M M M M M 89%
(men)
Diabetes 0  0 0 0 0 0    0   0 0 0  0 0 37%
Symptoms/ischemia at
follow-up
0   0   0 0   0 0   0    0 58%
Lesions treated 1 1 3 1 3 3 2 3 2 3 2 3 2 1 2 6 1 1 2 42
Lesions with restenosis 1 1 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1 20
(48%)
Vessel LAD LAD LAD DG SVG LAD LCx RCA RPL LCx DG DG LAD RCA LAD RCA SVG LCx RCA DG   
Procedural, angiographic,
and IVUS findings
Treatment of previous
in-stent restenosis
0 0 0 0 0 0 0 0 0 * 0 0 0 0  0  *  0 25%
Moderate/severe
calcification
0  0  0   0 0 0 0  0 0 0 0 0 0 0 0 25%
CTO 0 0 0 0   0 0 0 0 0 0    0 0   0 35%
Trauma outside the
stent/residual dissection
     0                                           83%†
Residual edge lesion‡ 0 0   0 0                                           33%†
After dilation with balloon
0.5 mm larger
 0  0  0 0 0 0  0 0 0 0    0   45%
Bifurcation stenting 0 0 § 0 0 § 0 0  0   0 § 0 0 0 0 0  35%
Ostial 0 0 0  0 0  0  0   0 0 0 0 0 0 0  30%
Stented length 33 mm 0 0  0  0 0  0 0 0 0 0    0   0 40%
2.25-mm diameter SES 0 0 0  0 0 0 0 0 0  0 0 0 0 0 0  0 0 15%
Stent fracture or gap
between stents¶
0 0 0 NA NA NA NA NA NA NA NA NA 0  0  0 0   50%#
Stent underexpansion at
restenosis site¶
0 0 0 NA NA NA NA NA NA NA NA NA  0 0 0  0 0 0 25%#
No. of any above
(diabetes)
2 3 5 5 4 3 2 1 3 3 4 2 3 5 4 3 3 5 5 4 Range
1–5
Post-SES restenosis
characteristics
Location prox prox prox prox prox prox in-st in-st in-
st
in-st in-
st
in-
st
in-st in-st in-st in-st in-st in-st in-st in-st
Total occlusion 0 0 0 0   0 0 0 0 0 0 0 0 0 0 0 0 0 0 10%
Focal lesion (length
10 mm)
   0 0 0     0 0  **     **  86%††
CTO indicates chronic total occlusion; DG, diagonal; IVUS, intravascular ultrasound; in-st, in-stent restenosis; LAD, left anterior descending; LCx, left circumflex
artery; NA, IVUS not available; prox, proximal edge restenosis; RCA, right coronary artery; RPL, right posterolateral branch; SES, sirolimus-eluting stent; SVG, saphenous
vein graft; , present; and 0, absent.
*After brachytherapy.
†Relative to proximal edge restenosis.
‡Angiographic diameter stenosis 30% or IVUS plaque burden 50%.
§Main vessel restenosis.
Side branch restenosis.
¶Diagnosed by IVUS.
#Relative to the No. of in-stent restenoses with available IVUS.
**More than 1 “focal” site.
††Relative to the No. of in-stent restenoses.
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Among the 14 in-stent lesions, 12 (86%) were focal
(restenosis length 10 mm)4 and presented a peculiar angio-
graphic pattern manifested by a very localized stenotic site
bordered by segments without evidence of lumen compro-
mise (Figure, A). Stenosis length decreased from
19.119.1 mm at baseline to 7.65.6 mm at follow-up
(P0.046). The ratio of restenosis length/stent length was
0.30.2. A gap between stents or stent fracture at the site of
the restenosis was detected by IVUS in 4 patients at follow-
up. A gap was diagnosed by the absence of stent struts in at
least one IVUS cross section in the examination of the region
between two stents (patients 13, 18, and 19); a stent fracture
was diagnosed by the nonvisualization of struts within the
stent (patients 15 and 18). One patient presented both stent
gap and fracture in separate sites (patient 18). In this patient,
no IVUS was performed at the index procedure (IVUS was
done only at follow-up). In the other patient with stent
fracture (patient 15), the stent discontinuity was not evident
after the procedure, being only detected at the follow-up. In
all cases, the stent gap or fracture could not be noticed
angiographically and measured 1 mm in length by IVUS
(Figure, A).
Among the 6 ostial lesions (30%), the ostium was not
covered by the stent at angiographic inspection in 1 case
(classified as proximal edge restenosis). The remaining 5
lesions appeared to be fully covered by the stent on angiog-
raphy. IVUS was available for only one of these cases. In this
patient, although angiographically unnoticed, a short area at
the ostium was observed to be uncovered by SES (Figure, B).
Among the 6 ostial lesions, 4 were located in the side branch
of bifurcation stenting treatment, all treated with “ T”stent
technique (stent in the side branch implanted with its proxi-
mal border located at the ostium of the branch; stent in the
main vessel implanted encompassing the side branch ostium,
thereby creating a “ T”configuration).5
Discussion
In 90% of patients with in-stent restenosis after SES
implantation, the lesion was very localized and bordered
by segments with no evidence of neointima. The effect of
the drug in the nonrestenotic portions indicates that an
intrinsic resistance to sirolimus was unlikely in most of our
patients. Among lesions evaluated by IVUS, stent discon-
tinuity was identified in 36% of cases (and in 50% of
restenosis located inside the stent), suggesting that a
decrease in local drug availability may have contributed to
the development of restenosis in these cases. Accordingly,
Focal restenosis at a gap between
stents. A, Short restenosis (angiogram,
arrowhead) was noted at site where no
stent struts were visualized on IVUS
examination (IVUS cross section, mid).
Stent coverage was complete at proxi-
mal and distal segments, with no neointi-
mal tissue present (IVUS cross sections
left and right, respectively). Longitudinal
IVUS reconstruction showed localized
pattern of restenosis. B, Ostial restenosis
(angiogram, arrowhead) was associated
with incomplete coverage by SES (IVUS
cross section left and longitudinal recon-
struction). Distal segment presented no
neointimal proliferation inside the stent
(IVUS cross section right and longitudinal
reconstruction).
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our findings suggest that incomplete lesion coverage by
the SES also may influence the occurrence of restenosis at
the stent borders and at ostial sites. We may speculate that
although no clinical data are currently available, tech-
niques that ensure complete vessel scaffolding could
constitute an alternative for SES implantation at bifurca-
tions.6 Edge restenosis occurred more frequently in the
proximal than in the distal stent border. Whether this
finding is associated with a more effective drug effect in
the outflow stent border remains to be clarified. In addi-
tion, 37% of our cases were diabetics. It may be hypoth-
esized that the presence of diabetes mellitus may lead to a
higher predisposition to post-SES restenosis.
The current study presents several limitations. Angio-
graphic follow-up was available for complex patients or for
those with recurrent symptoms, therefore precluding an
evaluation of the total restenosis rate for the global treated
population. Moreover, the lack of IVUS limits a more
detailed description of the mechanisms involved in the
occurrence of post-SES restenosis in some patients.
Conclusions
Restenosis after sirolimus-eluting stent placement occurs
within or adjacent to the stent. Edge restenosis is fre-
quently associated with local trauma outside the stented
segment. In-stent restenosis occurs as a very localized
lesion, associated with complex anatomy (especially ostial
lesions), stent discontinuity, or diabetes. A systemic drug
resistance to sirolimus seemed to be unlikely in most
patients.
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Sirolimus-Eluting Stent Implantation in ST-Elevation Acute
Myocardial Infarction
A Clinical and Angiographic Study
Francesco Saia, MD; Pedro A. Lemos, MD; Chi-Hang Lee, MD; Chourmouzios A. Arampatzis, MD;
Angela Hoye, MB ChB, MRCP; Muzaffer Degertekin, MD; Kengo Tanabe, MD;
Georgios Sianos, MD, PhD; Pieter C. Smits, MD, PhD; Eugene McFadden, MB ChB, MRCPI;
Sjoerd H. Hofma, MD; Willem J. van der Giessen, MD, PhD; Pim J. de Feyter, MD, PhD;
Ron T. van Domburg, PhD; Patrick W. Serruys, MD, PhD
Background—Sirolimus-eluting stents (SES) have recently been proven to reduce restenosis and reintervention compared
with bare stents. Safety and effectiveness of SES in acute myocardial infarction remain unknown.
Methods and Results—Since April 16, 2002, a policy of routine SES implantation has been instituted in our hospital, with
no clinical or anatomic restrictions, as part of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam
Cardiology Hospital) registry. During 6 months of enrollment, 96 patients with ST-elevation acute myocardial infarction
underwent percutaneous recanalization and SES implantation; these patients comprise the study population. The
incidence of major adverse cardiac events (death, nonfatal myocardial infarction, reintervention) was evaluated.
Six-month angiographic follow-up was scheduled per protocol. At baseline, diabetes mellitus was present in 12.5% and
multivessel disease in 46.9%. Primary angioplasty was performed in 89 patients (92.7%). Infarct location was anterior
in 41 (42.7%) of the cases, and 12 patients (12.5%) had cardiogenic shock. Postprocedural TIMI-3 flow was achieved
in 93.3% of the cases. In-hospital mortality was 6.2%. One patient (1.1%) had reinfarction and target lesion
reintervention the first day as a result of distal dissection and acute vessel occlusion. During follow-up (mean follow-up
of 21875 days), 1 patient died (1.1%), no patient had recurrent myocardial infarction, and there were no additional
reinterventions. No early or late stent thromboses were documented. At angiographic follow-up (70%), late loss was
0.040.25, and no patient presented angiographic restenosis.
Conclusions—In this study, sirolimus-eluting stent implantation for patients with ST-elevation acute myocardial infarction
was safe without documented angiographic restenosis at 6 months. (Circulation. 2003;108:1927-1929.)
Key Words: myocardial infarction  drugs  stents  restenosis
Routine stent implantation has been shown to have a betterprocedural success rate and clinical outcome than bal-
loon angioplasty in patients presenting with acute myocardial
infarction (AMI).1 However, in-stent restenosis and vessel
reocclusion remain significant clinical problems limiting the
long-term success of percutaneous treatment.1,2
Sirolimus-eluting stents (SES) have been proven to virtu-
ally abolish in-stent restenosis in elective patients with
relatively simple lesions,3 with persistent neointimal growth
inhibition up to 2 years.4 Recently, we have demonstrated that
the 30-day outcomes of SES implantation for patients with
acute coronary syndromes were similar to those of a control
population treated with bare stents.5 Nevertheless, no specific
information is presently available regarding the safety of
these new devices in patients with AMI. Furthermore, the
long-term clinical efficacy of SES for AMI is unknown. The
rationale of the present study is therefore to evaluate the
short- and midterm clinical and angiographic outcomes of
SES implantation in a consecutive series of patients treated
during the acute phase of AMI.
Methods
Patient Population
Since April 16, 2002, SES implantation (Cypher; Johnson & John-
son, Cordis Europa NV, Roden, the Netherlands) has been instituted
as the default strategy for all percutaneous coronary interventions
performed at our institution as part of the Rapamycin-Eluting Stent
Evaluated At Rotterdam Cardiology Hospital (RESEARCH) regis-
try, which has been described elsewhere.5 All clinical situations and
lesion morphologies were considered eligible. After 6 months of
enrollment, 96 consecutive patients within 12 hours of an episode of
AMI underwent mechanical reperfusion of the infarct-related artery
Received June 30, 2003; revision received September 2, 2003; accepted September 2, 2003.
From the Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.
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with SES implantation; these patients comprise the present study
population.
Procedure
Except for SES utilization, all procedures were performed according
to standard techniques, and the final interventional strategy was left
to the discretion of the operator. Weight-adjusted heparin was
administered to achieve an activated clotting time of 300 seconds,
or 200 to 250 seconds when platelet glycoprotein IIb/IIIa inhibitor
was used. Postprocedural antiplatelet regimen consisted of lifelong
aspirin use and 75 mg clopidogrel per day for 3 months. Prolonged
clopidogrel prescription (6 months) was recommended for patients
with at least one of the following characteristics: multiple SES (3
stents), total stent length 36 mm, bifurcations, or in-stent resteno-
sis. The local ethics committee approved the study protocol, and
informed consent was obtained from all patients.
Definitions and Follow-Up
Patients were evaluated for the occurrence of death, reinfarction
(clinical symptoms or new electrocardiographic changes, associated
with re-elevation of the creatine kinase and creatine kinase MB
levels of 1.5 times the previous value if within 48 hours, 3 times
the upper normal limit if after 48 hours),2 and target lesion revascu-
larization (surgical or percutaneous reintervention motivated by a
significant stenosis located within the stent or in the 5-mm segments
proximal or distal to the stent). Information regarding repeat inter-
ventions was prospectively collected in the local database. Survival
status was assessed by written inquiries to the Civil Registry.
Questionnaires to assess clinical status were sent to all living
patients. The patient, referring physician, and peripheral hospitals
were directly approached whenever necessary for additional
information.
To evaluate the incidence of restenosis after SES implantation for
AMI, angiographic follow-up was scheduled at 6 months for all
living patients. Binary restenosis was defined as a stenosis diameter
50% within the stent or in the 5-mm segments proximal or distal
to the stent. Late loss was defined as the difference between the
minimal luminal diameter immediately after the procedure and at
follow-up.
Statistical Analysis
Continuous variables are expressed as meanSD. Discrete variables
are presented as count and percentages. Event-free survival curves
were estimated according to the Kaplan-Meier method. Patients lost
to follow-up were considered at risk until the date of last contact, at
which point they were censored.
Results
At baseline, mean age was 5712 years. Twelve patients
(12.5%) had diabetes mellitus, 10 (10.4%) had had a previous
myocardial infarction, and 45 (46.9%) presented multivessel
disease. Six patients (6.2%) had prior coronary angioplasty,
and 1 (1%) had prior coronary bypass surgery. Mean creatine
kinase level was 26852869 IU/L. Average time from the
onset of symptoms to the beginning of the procedure was
3.62.9 hours. Primary angioplasty was performed in 89
patients (92.7%) and rescue angioplasty after failed
thrombolysis in the remaining 7 (7.3%). Cardiogenic shock
was diagnosed in 12 patients (12.5%). Periprocedural glyco-
protein IIb/IIIa inhibitor (abciximab) was used in 45 patients
(46.9%). Infarct location was anterior in 41 cases (42.7%).
Overall, 104 culprit lesions were identified (in 8 patients, we
found 2 different lesions anatomically and clinically related
to the development of the AMI). The lesions were located in
the left main in 2 cases (1.9%), the left anterior descending in
51 (49.0%), the left circumflex in 10 (9.6%), and the right
coronary in 41 (39.4%). Before the procedure, TIMI flow 0 to
1 was present in 60.6% of the cases. Postprocedural TIMI-3
flow was achieved in 93.3%. Clopidogrel was prescribed for
3 months in 54% of patients and for 6 months in the
remaining cases.
Complete follow-up was available for 99% of the patients
at 21875 days. A total of 6 deaths occurred during the index
hospitalization (6.2%). In 1 case, death occurred as a result of
brain death in a patient with prolonged out-of-hospital resus-
citation. The other 5 cases were all admitted in cardiogenic
shock; 3 of them died the same day of the procedure as a
result of progressive hemodynamic deterioration. The other 2
patients died of overwhelming sepsis at days 23 and 86 after
a prolonged, stormy course. One additional death (1.1%)
resulting from heart failure occurred during follow-up,
shortly after hospital discharge, in a 77-year-old patient with
3-vessel disease, who was admitted with a large inferoposte-
rior myocardial infarction and cardiogenic shock. In none of
these cases, death occurred as an unexpected, sudden episode
that could be attributable to stent thrombosis. Target lesion
reintervention was necessary in 1 patient (1.1%) the same day
as the procedure as a result of distal dissection, acute vessel
occlusion, and reinfarction. There were no further cases of
reinfarction or repeat intervention after discharge (Figure).
Also, no early or late stent thromboses were documented.
Six-month angiographic follow-up was obtained in 62
patients (70%). The angiographic outcomes are shown in the
Table. Late loss was 0.040.25 mm, and there were no
cases of binary restenosis.
Discussion
The present study is the first report on SES implantation for
patients with ST-elevation AMI. The main finding is that, in
these patients, SES implantation appears highly effective in
preventing neointimal proliferation and restenosis, with re-
sults similar to those observed in a randomized trial for
relatively simple lesions.3
Primary percutaneous coronary intervention has been dem-
onstrated to be more effective than thrombolytic therapy for
the treatment of AMI.6 However, although consistently re-
Kaplan-Meier curves for survival, and survival free from myocar-
dial infarction (MI) and target lesion revascularization (TLR). The
almost complete overlap of the curves, motivated by the very
low incidence of recurrent myocardial infarction and reinterven-
tions, is evident.
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duced by stent utilization, recurrent ischemia, restenosis, and
reocclusion of the infarct-related artery occur in sizable
proportions, increasing clinical events and healthcare costs.
In the Stent PAMI (Stent Primary Angioplasty for Myocar-
dial Infarction) trial, 6-month restenosis and target vessel
revascularization rates were 20.3% and 7.7%, respectively.2
In the CADILLAC (Controlled Abciximab and Device Inves-
tigation to Lower Late Angioplasty Complications) trial, the
corresponding values were 22.2% and 8.9%, and reocclusion
of the infarct-related artery 5.7%.1 In this context, the absence
of restenosis and reinterventions by SES as found in our study
could further improve clinical outcomes, although this hy-
pothesis should be tested in dedicated randomized trials.
Previous preclinical laboratory data suggested that siroli-
mus could decrease endothelial function in vitro,7 enhance
agonist-induced platelet aggregation,8 and delay vascular
healing.9 Altogether, these features can potentially increase
the risk of thrombotic complications and adversely affect the
outcome after SES implantation, especially in very suscepti-
ble patients such as those treated during the acute phase of
myocardial infarction. However, the clinical significance of
these preliminary findings remains elusive. Indeed, we re-
cently demonstrated the safety of SES for patients with acute
coronary syndromes, although AMI at presentation was still
associated with an increased risk of adverse events at follow-
up.5 The present study, with the very low event rate and the
absence of episodes of acute and subacute thrombosis,
confirms the safety of SES utilization, specifically in patients
with AMI.
In this prospective, single-center registry of SES implan-
tation in AMI, all the limitations inherent to this particular
study design apply, and the patient number was relatively
small. Notably, however, given the unrestricted inclusion
criteria, this cohort of patients accurately reflects the daily
practice in the “real world” of interventional cardiology, and
therefore the results are extended to virtually all patients with
AMI as a result of occlusion of native coronary vessels.
Conclusions
Routine SES implantation during mechanical reperfusion of
AMI is safe and associated with no evidence of late luminal
loss and restenosis at 6 months. Larger studies are necessary
to confirm these findings and to evaluate the impact of SES
implantation on clinical events for patients with AMI.
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Quantitative Coronary Analysis in Patients With AMI Treated With
Sirolimus-Eluting Stents
Before Procedure After Procedure Follow-Up*
Reference diameter, mm 2.730.59 2.800.47 3.040.49
Minimum lumen diameter, mm 0.340.50 2.541.31 2.590.42
Diameter stenosis, % 8621 1412 1511
Lesion length, mm 16.909.93      
Late loss, mm       0.040.25
Binary restenosis, %       0
*Values related to 62 patients with 6-month angiographic follow-up.
Saia et al Sirolimus-Eluting Stent in AMI 1929
86
Chapter 9
Short- and Long-Term Clinical Benefit of Sirolimus-Eluting Stents
87
SIROLIMUS-ELUTING 
STENT IMPLANTATION 
IN PATIENTS WITH 
ACUTE MYOCARDIAL 
INFARCTION
CHAPTER 10
Short- and Long-Term Clinical Benefit of 
Sirolimus-Eluting Stents Compared to 
Conventional Bare Stents for Patients With 
Acute Myocardial Infarction
Authors: Pedro A. Lemos, Francesco Saia, 
Sjoerd H. Hofma, Joost Daemen, Andrew T. Ong, 
Chourmouzios A. Arampatzis, Angela Hoye, 
Eugene McFadden, Georgios Sianos, Pieter C. 
Smits, Willem J. van der Giessen, Pim de Feyter, 
Ron T. van Domburg, Patrick W. Serruys. 
Circulation 2003;108:1927-1929
PART 3
88
Chapter 10
Short- and Long-Term Clinical Benefit of Sirolimus-Eluting Stents
89
EXPRESS PUBLICATION
Short- and Long-Term Clinical Benefit of Sirolimus-
Eluting Stents Compared to Conventional Bare
Stents for Patients With Acute Myocardial Infarction
Pedro A. Lemos, MD, Francesco Saia, MD, Sjoerd H. Hofma, MD, Joost Daemen,
Andrew T. L. Ong, MBBS FRACP, Chourmouzios A. Arampatzis, MD, Angela Hoye, MBCHB, MRCP,
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Willem J. van der Giessen, MD, PHD, Pim de Feyter, MD, PHD, FACC, Ron T. van Domburg, PHD,
Patrick W. Serruys, MD, PHD, FACC
Rotterdam, The Netherlands
OBJECTIVES This study investigated the clinical outcomes of patients with ST-segment elevation
myocardial infarction (MI) treated with sirolimus-eluting stents (SESs) or with conventional
bare stents.
BACKGROUND The clinical impact of SES implantation for patients with ST-segment elevation MI is
currently unknown.
METHODS Primary angioplasty was performed with SESs in 186 consecutive patients with acute MI who
were compared with 183 patients treated with bare stents. The incidence of death,
reinfarction, and repeat revascularization was assessed at 30 and 300 days.
RESULTS Postprocedure vessel patency, enzymatic release, and the incidence of short-term adverse
events were similar in both the sirolimus and the bare stents (30-day rate of death,
reinfarction, or repeat revascularization: 7.5% vs. 10.4%, respectively; p  0.4). Stent
thrombosis was not diagnosed in any patient in the sirolimus group and occurred in 1.6% of
patients treated with bare stents (p  0.1). At 300 days, treatment with SESs significantly
reduced the incidence of combined adverse events (9.4% vs. 17%; hazard ratio [HR] 0.52
[95% confidence interval (CI) 0.30 to 0.92]; p  0.02), mainly due to a marked reduction in
the risk of repeat intervention (1.1% vs. 8.2%; HR 0.21 [95% CI 0.06 to 0.74]; p  0.01).
CONCLUSIONS Compared to conventional bare stents, the SESs were not associated with an increased risk
of stent thrombosis and were effective in reducing the incidence of adverse events at 300 days
in unselected patients with ST-segment elevation acute MI referred for primary
angioplasty. (J Am Coll Cardiol 2004;43:704–8) © 2004 by the American College of
Cardiology Foundation
Routine stent implantation has been advocated for patients
with acute myocardial infarction (MI) referred for primary
angioplasty, with superior results compared to balloon
dilation (1–3). However, the late clinical efficacy is still
hampered by the occurrence of in-stent restenosis and the
need for repeat intervention.
Sirolimus-eluting stents (SESs) have proven to be effec-
tive in reducing late restenosis compared to conventional
stenting in elective patients (4–6). We have recently shown
in a relatively small consecutive series of cases that SES
implantation in patients with acute MI was safe and
associated with an extremely low (zero) incidence of angio-
graphic restenosis at six months (7). However, the clinical
benefit of SESs in comparison to conventional stent im-
plantation remains currently unknown. Therefore, we eval-
uated the long-term clinical outcomes of a large series of
patients with acute MI treated with primary angioplasty
utilizing either SESs or conventional metal stents.
METHODS
Since April 2002, SES implantation (Cypher, Johnson &
Johnson-Cordis unit, Cordis Europa NV, Roden, The
Netherlands) has been utilized as the strategy of choice for
patients treated with percutaneous intervention in our in-
stitution (8). Up until January 2003, a total of 186 consec-
utive patients with ST-segment elevation acute MI have
been treated with primary angioplasty utilizing exclusively
SESs and were included in the present report. The first 89
patients of the present series were included in an angio-
graphic substudy, of which the results have been reported
previously (7). A control group for comparison was com-
posed of 183 consecutive patients with ST-segment eleva-
tion acute MI treated with conventional bare stents in the
period immediately before the introduction of SESs. The
following bare metal stents were used: BX Sonic or BX
Velocity in 53% (Cordis, Johnson & Johnson, Warren, New
Jersey); Multi-Link Penta in 22% (Guidant Corp., Santa
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Clara, California); Multi-Link Tetra in 6% (Guidant
Corp.); R-Stent in 6% (Orbus Medical Technologies, Fort
Lauderdale, Florida), and other stents in 12%. In both study
phases, all patients were enrolled regardless of the clinical or
anatomical presentation, including patients admitted with
cardiogenic shock (defined as persistent systolic blood pres-
sure90 mmHg, or the need of vasopressors or intra-aortic
balloon pumping required to maintain blood pressure 90
mm Hg with evidence of end-organ failure and elevated left
ventricular filling pressures). Therefore, the total study
population comprised all 369 consecutive patients with
ST-segment elevation acute MI undergoing primary angio-
plasty with either bare stents or SESs in the two study
phases, respectively. Patients with angioplasty after failed
thrombolytic therapy were excluded from the present anal-
ysis. This study protocol was approved by the local ethics
committee, and written informed consent was given by
every patient.
The final interventional strategy, as well as the utilization
of periprocedural glycoprotein IIb/IIIa inhibitors and anti-
thrombotic medications, was entirely left to the discretion of
the operator. Baseline and postprocedure anterograde flow
were evaluated off-line according to the Thrombolysis In
Myocardial Infarction (TIMI) criteria (9) by cardiologists
blinded to both the stent group and to the clinical outcomes.
Clopidogrel was recommended for at least one month in the
control group. In the SES group, clopidogrel was prescribed
for three months, unless one of the following was present (in
which case clopidogrel was maintained for at least six
months): multiple SES implantation (3 stents), total
stented length 36 mm, bifurcation stenting, and in-stent
restenosis.
Patients were prospectively followed for the occurrence of
major adverse cardiac events: 1) all-cause death, 2) nonfatal
MI, or 3) target vessel revascularization. Reinfarction was
diagnosed by recurrent symptoms and/or new electrocardio-
graphic changes in association with re-elevation of the
creatine kinase (CK) and CK-MB levels of 1.5 times the
previous value, if within 48 h, or3 times the upper normal
limit, if after 48 h from the index infarction (1,7). Target
vessel revascularization was defined as a repeat intervention
(surgical or percutaneous) driven by any lesion located in the
same epicardial vessel treated at the index procedure.
Thrombotic stent occlusion was angiographically docu-
mented as a complete occlusion (TIMI flow grade 0 or 1) or
a flow-limiting thrombus (TIMI flow grade 1 or 2) of a
previously successfully treated artery. Routine angiographic
follow-up was obtained only for patients treated with SESs
enrolled during the first six months; results of this subanaly-
sis have been previously reported (7).
Continuous variables were presented as mean  standard
deviation, and were compared using the Student unpaired t
test. Categorical variables were presented as counts and
percentages and compared with the Fisher exact test.
Survival free of adverse events was estimated using the
Kaplan-Meier method and differences between curves were
evaluated by the log-rank test. Cox proportional hazards
survival models were used to assess risk reduction. Multi-
variate analyses were performed to identify independent
predictors of long-term major adverse cardiac events. Base-
line and procedural characteristics associated with the inci-
dence of adverse events at univariate analysis (p value for
selection 0.2) were tested for their multivariate predictive
value (tested variables: SES utilization, diabetes, cardiogenic
shock, multivessel disease, culprit vessel, pre-procedure
TIMI flow, postprocedure TIMI flow, current smoking).
The final model was built by backward stepwise variable
selection with an entry and exit criteria set at the p  0.05
and p  0.1 levels, respectively.
RESULTS
Baseline characteristics were similar between both study
groups, except by an older age and a lower incidence of
previous MI in the sirolimus group (Table 1). Procedural
characteristics differed between both groups in terms of the
utilization of glycoprotein IIb/IIIa inhibitors (sirolimus:
37% vs. bare stents: 56%; p  0.01) and the number of
stents implanted (sirolimus: 1.9  1.2 vs. bare stents: 1.7 
1.0; p  0.03). As defined by the study protocol, the
duration of clopidogrel prescription was longer for patients
with sirolimus stents (Table 1).
No significant differences existed in the 30-day outcomes
between patients treated with sirolimus or bare stents (Table
2). Stent thrombosis was diagnosed in three patients (1.6%)
treated with bare stents and was not detected in the SES
group (p  0.1) (Table 2).
At 300 days, no differences were noted between both
study groups in the incidence of death and death or
reinfarction (Table 2). However, the incidence of 300-day
major adverse events was significantly lower in the sirolimus
stent group compared to the bare stent group (9.4% vs. 17%,
respectively; hazard ratio [HR] 0.52 [95% confidence inter-
val (CI) 0.30 to 0.92]; p  0.02) (Table 2, Fig. 1), mainly
due to a marked reduction in the risk of repeat intervention
(1.1% vs. 8.2%, respectively; HR 0.21 [95% CI 0.06 to
0.74]; p  0.01). A multivariate analysis was performed to
adjust for baseline and procedural imbalances between the
study groups (Table 3). Sirolimus-eluting stent utilization
was identified as an independent predictor of 300-day
death, reinfarction, or repeat revascularization (HR 0.53
[95% CI 0.29 to 0.95]; p  0.03).
Abbreviations and Acronyms
CI  confidence interval
CK  creatine kinase
HR  hazard ratio
MI  myocardial infarction
SES  sirolimus-eluting stent
TIMI  Thrombolysis In Myocardial Infarction
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DISCUSSION
The main finding of the present study was that SES
implantation was effective in reducing the incidence of
adverse events at 300 days in unselected patients with
ST-segment elevation acute MI, compared to conventional
bare stenting. Furthermore, the risk of subacute thrombosis
within the first 30 days did not appear higher compared
with bare metal stents. Sirolimus-eluting stents were asso-
Table 1. Baseline and Procedural Characteristics of Patients Treated With Bare Stents or SES
Implantation
Bare Stents
(n  183)
SES
(n  186) p Value
Male (%) 79 75 0.4
Age, yrs  SD 57  12 60  12 0.04
Diabetes (%) 12 11 0.9
Current smoking (%) 47 46 0.8
Previous myocardial infarction (%) 24 14 0.03
Previous angioplasty (%) 9 7 0.4
Previous bypass surgery (%) 3 2 0.3
Coronary disease 0.3
Single-vessel (%) 48 55
Double-vessel (%) 29 27
Triple-vessel (%) 24 18
Cardiogenic shock (%) 10 13 0.3
Time from symptom onset to angioplasty, h  SD 3.0  2.7 3.2  1.9 0.6
Infarct-related vessel 0.3
Right coronary artery (%) 30 37
Left anterior descending (%) 57 53
Left circumflex artery (%) 10 8
Left main coronary artery (%) 1 2
Bypass graft (%) 2 —
TIMI flow baseline 0.7
Grade 0/I (%) 73 73
Grade II (%) 15 17
Grade III (%) 13 10
TIMI flow after angioplasty 0.5
Grade 0/I (%) 4 2
Grade II (%) 17 15
Grade III (%) 79 83
Number of stents  SD 1.7  1.0 1.9  1.2 0.03
Glycoprotein IIb/IIIa inhibitor (%) 56 37 0.01
Clopidogrel prescription, months  SD 2.1  1.5 3.7  2.1 0.01
Peak CK, IU/l  SD* 3,957  5,135 3,126  3,126 0.1
Peak CK-MB, IU/l  SD† 319  230 296  255 0.5
*Upper limit of normal 199 IU/l. †Upper limit of normal 23 IU/l.
CK  creatine kinase; SD  standard deviation; SES  sirolimus-eluting stents; TIMI  Thrombolysis In Myocardial
Infarction.
Table 2. Kaplan-Meier Estimates of Adverse Events at 30 Days
and at 300 Days
Bare Stents
(n  183)
SES
(n  186)
p
Value
30-Day outcomes
Death (%) 5.5 5.9 1.0
Death or nonfatal reinfarction (%) 7.1 6.5 0.8
Target vessel revascularization (%) 4.4 1.1 0.1
Any event (%) 10.4 7.5 0.4
Stent thrombosis (%)* 1.6 0 0.1
300-Day outcomes
Death (%) 8.2 8.3 0.8
Death or nonfatal reinfarction (%) 10.4 8.8 0.5
Target vessel revascularization (%) 8.2 1.1 0.01
Any event (%) 17.0 9.4 0.02
*Angiographically documented stent thrombosis.
SES  sirolimus-eluting stents.
Figure 1. Survival free of reinfarction or target vessel revascularization in
the sirolimus-eluting stent and conventional stent groups. CI confidence
interval.
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ciated with a relative reduction of 48% in the risk of death,
reinfarction, or repeat intervention and a relative reduction
of 79% in the risk of repeat intervention at 300 days.
In our series, reperfusion treatment with SESs was
associated with similar rates of vessel patency, enzymatic
release, and 30-day complications compared to bare stents.
The death rate and the incidence of death or reinfarction
were similar in both study groups, but somewhat higher
than those reported in randomized trials with selected
patients (1,2). These findings most probably reflect the
unrestrictive inclusion criteria of our series (10), which
frequently enrolled patients not included in randomized
studies, as, for instance, cardiogenic shock, multivessel
disease, and unprotected left main lesions. Importantly,
stent thrombosis has not been identified in any patient
treated with sirolimus stents and occurred in three controls
(1.6%), with no statistical difference between the groups.
Although the incidence of stent thrombosis in the bare stent
group was at a somewhat higher range, our results in this
group were not discrepant from historical series with con-
ventional stents (1,2,11–13).
Coronary stenting for the treatment of acute MI has been
limited by the need of late repeat intervention, which has
been reported to occur in approximately 9% of cases at six
months, ranging from 3.6% to 22.7% (1–3). The incidence
of repeat intervention after conventional stenting in our
series (8.2%) was in line with these previous figures. Con-
versely, patients treated with SES implantation clearly had a
reduced risk of reintervention at 10 months. Of note,
between 30 days and 10 months, no additional patient was
referred for repeat revascularization, which is consistent
with the lack of angiographic restenosis after sirolimus stent
implantation, as previously shown in a subset of patients
from the present population (7).
The peri- and postprocedural antiplatelet therapeutic
scheme differed between patients treated with either bare or
sirolimus stents in our series. Patients in the sirolimus group
received fewer glycoprotein IIb/IIIa inhibitors but had a
longer clopidogrel prescription time. However, none of
these characteristics were identified as independent predic-
tors influencing the outcomes of patients. The impact of
clopidogrel and glycoprotein IIb/IIIa inhibitors on the
long-term clinical outcomes of patients with ST-segment
elevation acute MI remains to be established (2,14,15).
Conclusions. Sirolimus-eluting stent implantation for un-
selected patients with ST-segment elevation acute MI
was associated with similar procedural and 30-day out-
comes compared to bare stents, but markedly reduced the
risk of major adverse events and repeat intervention at 10
months. By providing effective mechanical reperfusion
with similar results to the current therapeutic standard,
and decreasing the incidence of late complications, SESs
appeared as an attractive approach for patients admitted
with acute MI. The promising results of the present study
warrant further confirmation in the context of a random-
ized trial.
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SUMMARY AND CONCLUSIONS
Drug-eluting stents (DES) represent a new breakthrough biotechnology wich combines coronary 
stent implantation and local drug-delivery. Sirolimus and paclitaxel-eluting stents have been 
shown in randomised trials to prevent local neointimal formation and to drammatically reduce 
restenosis as compared with conventional bare metal stents.
However, thus far the implementation of DES in clinical practice has been limited by cost issues 
and to some reluctance in transferring the positive results of randomised trials to the real-world 
scenario without the support of scientific evidence of efficacy.
Therefore, to test whether broadening the indications for drug-eluting stent utilization in daily 
practice is safe and effective, we assessed the outcomes of sirolimus-eluting stent implantation 
in clinical conditions and in coronary lesions generally excluded from randomised trials.
DRUG-ELUTING STENTS TO TREAT IN-STENT RESTENOSIS
To date, in-stent restenosis (ISR) still represents the major limitation of percutaneous coronary 
intervention, even if the development of drug-eluting stents is giving rise to the reasonable 
hope that neointimal hyperplasia growth and luminal renarrowing following coronary stent 
implantation could be very efficiently prevented.
Treatment of ISR is frequently a challenging clinical problem, with recurrent restenosis being 
reported in up to 80% in the most complex cases. Vascular brachytherapy (VBT), by targeting 
the “biological” component of neointimal proliferation, is the only strategy proven to be effective 
in randomized trials. However, its utilization is limited by complex logistic requirements and the 
necessity of highly trained operators.
Sirolimus-eluting (SES) implantation for the treatment of in-stent restenosis was tested in two 
preliminary studies with a very limited number of patients. Therefore we evaluated the clinical 
and angiographic outcomes of 44 consecutive patients treated with routine SES implantation 
for in-stent restenosis in a broad range of morphological lesion patterns, as commonly seen in 
daily practice. We showed that routine sirolimus-eluting stent implantation was highly effective 
for focal in-stent restenosis and appeared to be a promising strategy for more complex patterns 
of restenosis. When compared to patients with similar clinical characteristics and lesion patterns 
treated with vascular brachytherapy, SES implantation appeared to be at least as effective at 9 
months clinical follow-up.
We reported also the first experience of SES implantation to treat patients with recurrent 
in-stent restenosis following failed brachytherapy. We concluded that SES implantation in these 
patients is safe and clinically effective, although they clearly represent a peculiar subset of 
patients in which SES are less effective in preventing neointimal hyperplasia, for reasons that 
would require further investigations.
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UNRESTRICTED UTILIZATION OF DRUG-ELUTING STENTS
The second part of this thesis is focused on the evaluation of the impact of SES on the 
outcomes of patients treated in the “real world” of interventional cardiology, as compared with 
a strategy using conventional bare stent implantation. Therefore, we adopted SES implantation 
as the default strategy to accomplish percutaneous coronary interventions at our institution, 
without any contraindication (with the exception of unavailability of properly sized devices). 
The outcome was compared with that of patients treated with bare metal stent implantation in 
the period immediately before SES commercialisation. We proved that unrestricted utilization 
of SES in the “real world” is safe, through a preliminary analysis of the incidence of mid-term 
thrombotic stent occlusion, and is effective in reducing the need of further revascularization and 
the incidence of major adverse cardiac events after 1 year.
To be routinely used, a new stent should be safe in all procedural conditions. Direct stenting, 
overlapping stents, post-dilatation, and others are fields that deserve specific investigation. In 
daily practice, post-deployment dilatation of the stent with oversized balloons on the basis of 
angiographic or intravascular ultrasound findings is quite common. Although not recommended, 
extreme over-dilatation with balloon >1mm larger than the stent nominal size might be required 
in selected cases to achieve a good procedural result. With available drug-eluting stents, 
appropriate drug delivery depends on the polymer integrity and on the proper spatial distribution 
of the stent struts. Post-dilatation of the stent could impair the effectiveness of SES in different 
ways: by enhancing tissue proliferation in response to greater vessel injury, by altering the 
mechanical properties of the stent, by disrupting the polymer coating, and by increasing the 
distance between the stent struts. Therefore, we assessed the outcomes of patients treated 
with SES implantation in which a post-dilatation with largely oversized balloons was performed, 
and showed that this strategy is safe and apparently does not compromise SES efficacy.
Finally, we described the clinical and morphological patterns of restenosis after sirolimus-
eluting stent implantation, and we observed that edge restenosis is frequently associated with 
local trauma outside the stent, whilst in-stent restenosis occurs as a localized lesion, commonly 
associated with a discontinuity in the stent coverage or local conditions rather that intrinsic drug-
resistance to sirolimus.
DRUG-ELUTING STENTS FOR ST-ELEvATION ACUTE MYOCARDIAL INFARCTION
Routine stent implantation has been advocated for patients with acute myocardial infarction 
referred for primary angioplasty, with superior results compared to balloon dilatation. In the 
third part of this thesis, results of the first experience of sirolimus-eluting stents implantation 
in patients with acute myocardial infarction are reported. In this subset, SES appeared safe 
and associated with an extremely low (zero) incidence of angiographic restenosis at 6 months. 
Moreover, this strategy achieved similar procedural and 30-days outcomes compared to bare 
stents, but markedly reduced the risk of major adverse events and repeat intervention at 10 
months.
Summary and Conclusions
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A GLIMpSE INTO THE FUTURE
As already pointed out, widespread utilization of drug-eluting stents in clinical practice has 
been limited by cost issues and, to a lesser extend, by the fact that available data referred to 
a limited number of patients, with selected low-risk clinical conditions and lesions. However, 
the body of evidence for a dramatic reduction of in-stent restenosis with drug-eluting stents is 
sharply increasing to include large number of patients with all clinical and anatomical conditions. 
Therefore, we might speculate that drug-eluting stents will slowly subside bare metal stents, 
being the initially higher costs of presumably ephemeral nature.
It appears now clear that complete abolition of in-stent restenosis, as hypothesized after 
publication of the RAVEL trial results, was merely a dream. Although strongly reduced and 
apparently presenting with a favourable focal pattern, in-stent restenosis following drug-eluting 
stent implantation will deserve some attention to select appropriate treatment and outcomes.
The drug-eluting stent era has just begun. A large number of new drugs and coatings are 
under investigations and will slowly appear in the market. As our understanding of the interaction 
between these drugs, the vessel wall and the patients will increase, we might be able to develop 
tailored stents for different clinical conditions and lesions (for example, with increased amount 
of the drug or prolonged release for patients at very high-risk for restenosis).
The complex balance between drug antiproliferative effect and vessel wall healing after 
the intervention, could be improved with new stent coatings, and some are already under 
development.
In the near future, the concept of stent drug elution might be further expanded. In fact, some 
manufacturers have developed new stents which can be loaded with different drugs, in variable 
amounts, which can be released with different kinetics, and with a differentially directed elution 
(toward the vessel wall or the blood stream). Primary angioplasty for acute myocardial infarction 
might well represent the ideal field of application of such a stent, with an antiproliferative 
drug directed toward the vessel wall to take care of restenosis, and a specific drug released 
downstream to improve microvascular reperfusion or to promote myocardial tissue repair.
Finally, biodegradable stents are under investigation. The possible combination between a 
biodegradable stent platform and a specific drug is very appealing. It might be routinely used, 
and it might also represent a tool to treat atherosclerotic lesions which are not obstructive but 
that are recognised by appropriate means (under development as well) to be “vulnerable”, i.e. 
associated with increased risk to originate acute coronary events.
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SAMENvATTING EN CONCLUSIES
Gecoate stents vertegenwoordigen een nieuwe baanbrekende biotechnologie die coronaire stent 
implantatie combineert met locale geneesmiddelentherapie. Gerandomiseerde studies hebben 
bewezen dat sirolimus- en paclitaxel gecoate stents neointima formatie kunnen voorkomen en 
restenose drastisch kunnen verminderen in vergelijking tot de conventionele stents.
Tot nog toe werd het gebruik van gecoate stents in de hedendaagse praktijk beperkt door 
hogere kosten en door enige terughoudendheid in het overbrengen van de positieve resultaten 
van gerandomiseerde studies in een scenario dat dichter bij de dagelijkse praktijk ligt, zonder 
de steun van wetenschappelijke bewijzen en efficiëntie. 
Om te testen of het verbreden van het indicatiegebied voor gecoate stents in de dagelijkse 
praktijk veilig en effectief is, beoordeelden wij de resultaten van het gebruik van sirolimus 
gecoate stent implantatie in klinische situaties die normaal geëxcludeerd zouden zijn in 
gerandomiseerde studies.
 
GECOATE STENTS TER BEHANDELING vAN IN-STENT RESTENOSE
Tot nu toe is in-stent restenose (ISR) nog steeds de grootste beperking van percutane coronaire 
interventies, ondanks het feit dat de ontwikkeling van gecoate stents reële hoop geeft dat 
neointima hyperplasie en vernauwing van het vaatlumen na coronaire stent implantatie zeer 
effectief tegengegaan zou kunnen worden.
Behandeling van ISR is regelmatig een uitdagend klinisch probleem, met terugkerende 
restenose percentages oplopend tot 80% in de meest complexe gevallen. Vasculaire 
brachytherapie (VBT), die de “biologische” component van neointima proliferatie tegengaat, 
is de enige strategie die in gerandomiseerde studies effectief is gebleken. Het gebruik hiervan 
wordt echter beperkt door de behoefte aan een complexe organisatie met betrekking tot formele 
goedkeuringen en hoog opgeleide operateurs.
Sirolimus gecoate stent implantatie voor de behandeling van in-stent restenose is onderzocht 
in twee voorafgaande studies met een zeer beperkt aantal patiënten. Daarom hebben wij het 
klinische en angiografische resultaat van 44 opeenvolgende patiënten die behandeld zijn met 
een routine sirolimus gecoate stent implantatie voor in-stent restenose beoordeeld in een breed 
gebied van laesiepatronen zoals frequent gezien in de dagelijkse praktijk. Wij konden aantonen 
dat routine sirolimus gecoate stent implantatie zeer effectief was in het behandelen van focale 
in-stent restenose en deze behandeling bleek een veelbelovende strategie voor complexe 
vormen van restenose. Wanneer vergeleken met patiënten met dezelfde klinische presentatie 
en laesies behandeld met brachytherapie, bleek sirolimus gecoate stent implantatie zeker zo 
effectief na 9 maanden van klinische follow-up.
Ook publiceerden wij de eerste ervaringen van behandeling van patiënten met terugkerende 
in-stent restenose na niet succesvolle brachytherapie behandeld met sirolimus gecoate stents.
Concluderend kunnen wij zeggen dat het gebruik van sirolimus gecoate stents in deze 
patiënten veilig en klinisch effectief is, ook al representeren zij een zeer specifieke groep van 
patiënten waarin het gebruik van de sirolimus gecoate stents minder effectief is in het tegengaan 
van neointima hyperplasie. Naar de oorzaak hiervan zal dan ook nog verder onderzoek verricht 
moeten worden.
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ONBEpERkT GEBRUIk vAN GECOATE STENTS
Het tweede gedeelte van dit proefschrift richt zich op het beoordelen van het gebruik van sirolimus 
gecoate stents in een patiëntenpopulatie uit de dagelijkse praktijk van de interventiecardiologie 
vergeleken met het gebruik van conventionele stents. Om deze reden hebben we in onze 
instelling de sirolimus gecoate stent als standaard behandeling voor alle percutane coronaire 
interventies gebruikt, zonder enige contra-indicaties, met uitzondering van het in bepaalde 
gevallen niet beschikbaar zijn van stents in de juiste maat. De resultaten van dit beleid hebben 
we vergeleken met de resultaten van de behandeling van patiënten waarin conventionele stents 
gebruikt waren, in een periode vlak voor de introductie van de sirolimus gecoate stents. We 
hebben bewezen dat onbeperkt gebruik van de sirolimus gecoate stent in de dagelijkse praktijk 
veilig is, door een voorafgaande analyse van de incidentie van trombotische stent occlusie op 
middenlangetermijn, en dat de sirolimus gecoate stent effectief is in het terugbrengen van de 
behoefte aan latere revascularisatie en cardiale events 1 jaar na follow-up.
Om als routine behandeling gebruikt te kunnen worden, moet een nieuwe stent in alle 
klinische situaties veilig zijn. Direct stenten, overlappende stents, na-dilatatie en anderen, zijn 
gebieden waarop specifiek onderzoek verricht zal moeten worden. In de dagelijkse praktijk 
is dilatatie na ontplooiing van de stent met ballonnen met een diameter groter dan die van 
de stent op basis van angiografische of intravasculaire echoresultaten vrij gewoon geworden. 
Ondanks het niet aanbevolen worden hiervan kan extreme over-dilatatie met ballonnen groter 
dan 1mm boven de nominale grootte van de stent in specifieke gevallen noodzakelijk zijn om 
een goed behandelingsresultaat te krijgen. Met de beschikbaarheid over gecoate stents, hangt 
gepaste medicijn afgifte af van de zuiverheid van de polymeer en van de afstand waarop de 
stentdraden van elkaar liggen. Nadilatatie zou de effectiviteit van de sirolimus gecoate stents 
op verschillende manieren nadelig kunnen beïnvloeden: door weefselproliferatie te bevorderen 
als gevolg van grotere beschadigingen van de vaatwand, door de mechanische eigenschappen 
van de stent te beïnvloeden, door het beschadigen van de polymeer coating en door het 
vergroten van de afstand tussen de stentdraden. Daarom beoordeelden wij de resultaten van 
de behandeling van patiënten met sirolimus gecoate stents waarin nadilatatie met te grote 
ballonnen was gedaan en toonden aan dat deze behandelingsstrategie veilig is en de efficiëntie 
van de sirolimus gecoate stent niet nadelig beïnvloed.
Tot slot beschreven wij de klinische en morfologische vormen van restenose na sirolimus 
gecoate stent implantatie en zagen we dat randrestenose frequent geassocieerd is met 
trauma buiten de stent, daar waar in-stent restenose vooral voorkomt als een locale laesie en 
vaak geassocieerd is met een discontinuïteit in de bedekking door de stent of de plaatselijke 
vaatwandtoestand, eerder dan door ongevoeligheid voor sirolimus.
GECOATE STENTS vOOR ACUTE MYOCARD INFARCTEN MET ST-ELEvATIE
Het gebruik van stents in de behandeling van patiënten met een acuut myocard infarct verwezen 
voor primaire angioplastiek heeft inmiddels de voorkeur gekregen boven de ballon dilatatie 
vanwege de betere resultaten. In het derde gedeelte van dit proefschrift zijn de eerste resultaten 
beschreven van de behandeling van acute myocard infarct patiënten met sirolimus gecoate 
stents. In deze patiëntenpopulatie heeft de sirolimus gecoate stent bewezen veilig te zijn en 
een extreem lage (nul) incidentie van angiografische restenose te geven na 6 maanden van 
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follow-up. Hierboven gaf deze strategie dezelfde procedurele resultaten als de conventionele 
stentbehandeling na 30 dagen van follow-up maar met een duidelijk lager risico op negatieve 
gebeurtenissen en herinterventies na 10 maanden van follow-up. 
EEN BLIk IN DE TOEkOMST
Zoals reeds besproken wordt het grootschalig gebruik van gecoate stents in de klinische praktijk 
beperkt door kostenkwesties en in mindere mate door het feit dat de beschikbare data verwijst 
naar een beperkt aantal patiënten met een beperking betreft klinische risico’s en laesies.
Maar, met een sterke toename van bewijs voor de drastische reductie van in-stent restenose 
met gecoate stents lijkt het mogelijk om een groter aantal patiënten te includeren zonder 
beperkingen met betrekking tot klinische en anatomische presentatie. Om deze reden mogen 
we speculeren dat gecoate stents langzaam de conventionele stents zullen vervangen ondanks 
de aanvankelijk hogere kosten van waarschijnlijk voorbijgaande aard.
Het lijkt nu duidelijk dat een “volledige” verdwijning van in-stent restenose, zoals geopperd 
na publicatie van de RAVEL studie resultaten enkel een droom was. Ondanks sterk verminderd 
en zich blijkbaar presenterend met een gunstig plaatselijk focus zal in-stent restenose na 
het gebruik van de gecoate stents verdere aandacht vergen om te kiezen voor een gepaste 
behandeling en resultaten.
Het tijdperk van de gecoate stent is pas begonnen. Er wordt onderzoek gedaan naar een 
groot aantal nieuwe geneesmiddelen en coatings (bijvoorbeeld, stents met een hogere medicijn-
load of verlengde afgifte hiervan voor patiënten met een hoger risico op restenose).
De complexe balans tussen medicijn geïnduceerde antiproliferatieve effecten en vaatwand 
genezing na behandeling zou kunnen worden verbeterd met nieuwe stent coatings en sommige 
zijn zeker in ontwikkeling.
In de nabije toekomst zal het idee van medicijnafgifte vanuit de stent verder uitgewerkt 
worden. Sommige producenten hebben zelfs al nieuwe stents ontwikkeld die verschillende 
soorten geneesmiddelen kunnen dragen, in verschillende dosis die kunnen worden afgegeven 
met andere kinetische eigenschappen en met een anders gereguleerde afgifte (naar de vaatwand 
of in de richting van de bloedstroom). Primaire angioplastiek voor acute myocard infarcten zou 
zich kunnen presenteren als het ideale gebied voor het gebruik van zulke stents, met een 
antiproliferatief geneesmiddel gericht tegen de vaatwand om restenose tegen te gaan en een 
meer specifiek middel met een afgifte in de richting van de bloedstroom om microvasculaire 
reperfusie te bevorderen of om genezing van het door een myocard infarct aangetast weefsel 
te bevorderen.
Tot slot wordt er onderzoek verricht naar bioresorbeerbare stents en de mogelijke combinatie 
van een bioresorbeerbare stent met een specifiek geneesmiddel lijkt zeer aantrekkelijk. Het 
zou als routinebehandeling gebruikt kunnen gaan worden en het zou ook een manier kunnen 
gaan vertegenwoordigen om atherosclerotische laesies te behandelen die niet obstructief zijn 
maar die erkend worden hiervoor “gevoelig” te zijn (ook in onderzoek), wat wil zeggen: laesies 
geassocieerd met een hoger risico coronaire events. 
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